?

Discussions and Knowledge Gaps

1

Can aggressive pulmonary vasodilator therapy render an inoperable Eisenmenger patient operable, and should the defect then be closed?

CONTROVERSY OPEN treat_and_repair_strategy

Attached to

pathophysiology#Right-to-left shunt as a protective right ventricular pop-off

The established position is that shunt closure must be avoided once Eisenmenger physiology exists, because the shunt is decompressing the right ventricle. The treat-and-repair strategy proposes that pulmonary vasodilators can lower pulmonary vascular resistance enough in selected responders to make closure safe again. Case series report good short- and medium-term outcomes, but there is no randomised evidence, no long-term follow-up, and no agreed haemodynamic threshold for eligibility. The stakes are asymmetric: closing the defect in a patient whose resistance does not stay down removes the pop-off irreversibly.

Proposed experiments

Prospective multicentre registry of treat-and-repair with predefined haemodynamic eligibility

exp_es_treat_and_repair_registry

Enrol patients with pulmonary arterial hypertension associated with congenital heart disease who meet a predefined post-treatment haemodynamic threshold, record whether closure was performed, and follow right ventricular function, functional class, and survival for at least five years against a matched non-closed comparison group.

Decision criterion

Sustained right ventricular function and survival at five years in closed patients, relative to matched unclosed controls, would justify a threshold-based recommendation; deterioration would confirm the current avoid-closure default.

Show evidence (1 reference)

PMID:33853494 SUPPORT Human Clinical

"Once Eisenmenger syndrome develops, shunt closure should be avoided."

States the default position that the treat-and-repair strategy proposes to qualify.

⚙

Pathophysiology

13

Uncorrected non-restrictive systemic-to-pulmonary shunt

The initiating lesion is a large congenital communication at the atrial, ventricular, or aortopulmonary level that is never closed, or is closed too late. Shunt level governs risk: post-tricuspid defects (ventricular septal defect, patent ductus arteriosus, atrioventricular septal defect, truncus arteriosus) transmit systemic pressure as well as flow to the pulmonary bed and carry much the higher risk, whereas pre-tricuspid atrial-level defects transmit volume alone and progress far less often and far later. Trisomy 21 with a post-tricuspid lesion accelerates the whole sequence.

Heart UBERON:0000948

Downstream

Shear-stress-mediated pulmonary endothelial dysfunction Chronic high pulmonary blood flow imposes abnormal shear stress on the pulmonary arterial endothelium.

Show evidence (2 references)

PMID:39711759 SUPPORT Human Clinical

"It develops in the presence of a non-restrictive communication at the aortopulmonary, ventricular, or atrial level."

Defines the anatomic substrate and the three levels at which the communication may sit.

PMID:27325590 SUPPORT Human Clinical

"The likelihood of being treated interventionally or surgically before the age of 1 year increased significantly over time. In parallel, the likelihood of developing ES decreased over time (53% birth cohort during 1950s/1960s vs 0.5% birth cohort during 2000-2009, p<0.0001)."

German National Register data in 894 Down syndrome patients with post-tricuspid shunts, showing that leaving the shunt uncorrected is what produces the syndrome, and that early repair all but abolishes it.

Shear-stress-mediated pulmonary endothelial dysfunction

Pulmonary arterial endothelial cells exposed to sustained abnormal shear stress lose homeostatic function, shifting the balance from vasodilation toward vasoconstriction and proliferation. Nitric oxide and prostacyclin production fall while endothelin-1 rises. This is the same endothelial lesion that initiates idiopathic and heritable pulmonary arterial hypertension, reached here by a mechanical rather than a genetic route, which is why the three endothelium-directed drug classes developed for those diseases also work in Eisenmenger syndrome.

Pulmonary artery endothelial cell CL:1001568

nitric oxide biosynthetic process GO:0006809 ↓ DECREASED

Pulmonary artery UBERON:0002012

Downstream

Pulmonary artery smooth muscle proliferation and vasoconstriction Loss of endothelial vasodilator tone and excess endothelin-1 drive medial smooth muscle proliferation and sustained vasoconstriction.

Show evidence (2 references)

PMID:16801459 SUPPORT Human Clinical

"Because Eisenmenger syndrome is associated with increased endothelin expression, patients may benefit from endothelin receptor antagonism."

Establishes increased endothelin expression as a feature of the syndrome, which is the rationale on which the endothelin-antagonist trial was built.

PMID:19245962 SUPPORT Human Clinical

"Although ES shares similar morphological findings with idiopathic PAH, clinical differences exist between the 2 etiologies."

Supports the shared pulmonary vascular lesion that underlies module conformance, while flagging that the two diseases are not clinically equivalent.

Pulmonary artery smooth muscle proliferation and vasoconstriction

Paracrine signals from the dysfunctional endothelium drive a pro-proliferative, anti-apoptotic switch in pulmonary artery smooth muscle cells together with sustained vasoconstriction, increasing medial cellularity. This is the amplifying step shared with all forms of pulmonary arterial hypertension.

Pulmonary artery smooth muscle cell CL:0002591

smooth muscle cell proliferation GO:0048659 ↑ INCREASED

Downstream

Obstructive pulmonary vascular remodeling Sustained medial proliferation progresses to fixed structural obstruction of the small pulmonary arteries.

Show evidence (1 reference)

PMID:16801459 SUPPORT Human Clinical

"Compared with placebo, bosentan reduced pulmonary vascular resistance index (-472.0 dyne.s.cm(-5); P=0.0383)."

Pharmacologic reversal of part of the resistance by blocking endothelin signalling implies a component of ongoing endothelin-driven vasoconstriction and proliferation rather than purely fixed obstruction.

Obstructive pulmonary vascular remodeling

Progressive structural obliteration of the small pulmonary arteries: medial hypertrophy, then intimal cellular proliferation and concentric fibrosis, then plexiform arteriopathy, the sequence graded histologically by Heath and Edwards. In situ thrombosis compounds the luminal loss. Once advanced, the lesion is irreversible, which is what converts a correctable congenital defect into an inoperable one.

blood vessel remodeling GO:0001974 ↕ DYSREGULATED

Pulmonary artery UBERON:0002012

Downstream

Increased pulmonary vascular resistance Loss of cross-sectional area in the small pulmonary arteries raises the resistance the right ventricle pumps against.

Show evidence (1 reference)

PMID:39711759 SUPPORT Human Clinical

"Longstanding left-to-right shunting associated with congenital heart disease (CHD) can ultimately lead to pulmonary vascular remodeling, pulmonary arterial hypertension, and shunt reversal, the hallmark feature of Eisenmenger Syndrome (ES)."

States the remodeling step and its position in the causal chain between the shunt and shunt reversal.

Increased pulmonary vascular resistance

Fixed structural obstruction plus a residual vasoconstrictive component raise pulmonary vascular resistance toward and beyond systemic levels. The degree of elevation and its reversibility on vasoreactivity testing are what determine whether any operability window remains.

Downstream

Shunt reversal to right-to-left or bidirectional flow When pulmonary vascular resistance equals or exceeds systemic vascular resistance, the pressure gradient across the defect inverts.

Pulmonary arterial hypertension with right ventricular pressure overload The right ventricle faces a chronically elevated afterload.

Show evidence (1 reference)

PMID:31120797 SUPPORT Human Clinical

"It is characterised by a severe rise in pulmonary vascular resistance resulting in shunt reversal and cyanosis."

Places the rise in pulmonary vascular resistance immediately upstream of shunt reversal and cyanosis.

Shunt reversal to right-to-left or bidirectional flow

The defining event. Once pulmonary vascular resistance matches or exceeds systemic resistance, deoxygenated blood crosses the defect into the systemic circulation instead of the reverse, producing chronic arterial hypoxaemia and central cyanosis. This node is what distinguishes Eisenmenger syndrome from every other form of pulmonary arterial hypertension and from earlier, still-operable stages of pulmonary arterial hypertension associated with congenital heart disease; it is deliberately not mapped onto the `pulmonary_vascular_remodeling` module, which has no counterpart for it.

Downstream

Chronic hypoxaemia and secondary erythrocytosis Systemic delivery of deoxygenated blood lowers arterial oxygen saturation.

Right-to-left shunt as a protective right ventricular pop-off The same reversed shunt that causes the hypoxaemia also unloads the pressurised right ventricle.

Loss of pulmonary filtration of venous emboli Venous thrombi and septic emboli bypass the pulmonary capillary bed and enter the systemic arterial circulation directly.

Show evidence (2 references)

PMID:39711759 SUPPORT Human Clinical

"Eisenmenger syndrome (ES) is defined as pulmonary hypertension due to a high pulmonary vascular resistance with reversed or bidirectional shunt"

The operational definition of the syndrome, making shunt reversal the defining node rather than an incidental consequence.

PMID:32690623 SUPPORT Human Clinical

"Central cyanosis is the primary clinical manifestation leading to secondary erythrocytosis and various multiorgan complications that increase morbidity and affect quality of life."

Connects the reversed shunt to cyanosis and onward to the multiorgan complication burden.

Right-to-left shunt as a protective right ventricular pop-off

A genuinely counterintuitive node, and the reason management differs from every other severe pulmonary arterial hypertension. By venting the pressure-loaded right ventricle into the systemic circulation, the reversed shunt preserves cardiac output and defers right ventricular failure, so patients with Eisenmenger syndrome survive longer and have more favourable haemodynamics than adults with idiopathic pulmonary arterial hypertension at comparable pulmonary pressures. The therapeutic corollary is that closing the defect once the physiology is established removes the pop-off and precipitates right heart failure, which is why shunt closure is contraindicated rather than curative at this stage.

Show evidence (2 references)

PMID:19245962 SUPPORT Human Clinical

"Adults with ES exhibit increased survival and more favorable hemodynamics than those with idiopathic PAH."

The comparative survival advantage over idiopathic pulmonary arterial hypertension, which is the observable consequence of the decompressing shunt.

PMID:33853494 SUPPORT Human Clinical

"Once Eisenmenger syndrome develops, shunt closure should be avoided."

The management corollary stated directly, namely that the defect must be left open once the physiology is established.

Pulmonary arterial hypertension with right ventricular pressure overload

Sustained elevation of pulmonary arterial pressure imposes chronic pressure overload on the right ventricle, driving hypertrophy and ultimately maladaptive remodeling and failure. Right heart failure remains the leading cause of death in the modern drug-therapy era, unchanged from before it.

cardiac muscle hypertrophy GO:0003300 ↑ INCREASED

Right ventricle UBERON:0002080

Downstream

Atrial arrhythmia and conduction system disease Chronic right-sided pressure overload and atrial stretch create the arrhythmic and conduction-system substrate.

Show evidence (1 reference)

PMID:39711759 SUPPORT Human Clinical

"in contemporary series, the most common cause of mortality remains right heart failure, unchanged from the pre-DTT era"

Establishes right heart failure as the dominant terminal event, and that modern drug therapy has not displaced it.

Atrial arrhythmia and conduction system disease

Chronic right atrial stretch and right ventricular pressure overload generate an arrhythmic substrate: atrial fibrillation, prolonged QRS duration, complete heart block, and right bundle branch block are all associated with sudden cardiac death in this population, and atrial fibrillation is by some margin the strongest independent predictor. This is the proximate route to the sudden deaths that make up a large share of mortality, and it is separable from the progressive pump failure that kills the rest. Notably, advanced pulmonary vasodilator therapy was strongly protective against sudden death in the same analysis.

Right atrium UBERON:0002078

Downstream

Sudden cardiac death Atrial fibrillation and conduction system disease are the arrhythmic substrate through which this disease produces sudden death, as distinct from the progressive pump failure that produces the rest of its mortality.

Show evidence (3 references)

PMID:32174228 SUPPORT Human Clinical

"Atrial fibrillation (11.45-fold increased risk; P<0.001) and QRS duration ≥120 ms (2.06-fold increased risk; P=0.034) remained significant predictors of SCD in the multivariate analysis, whereas advanced pulmonary hypertension therapies were strongly protective against SCD (P<0.001)."

Two-centre study of 246 patients identifying atrial fibrillation as the dominant independent predictor of sudden cardiac death, with pulmonary vasodilator therapy protective.

PMID:32174228 SUPPORT Human Clinical

"Atrial arrhythmias, impaired ventricular function, and conduction system disease were associated with increased risk of SCD in this cohort of patients with Eisenmenger syndrome"

Names the three associated domains curated in this node.

PMID:32174228 SUPPORT Human Clinical

"Clinical heart failure symptoms (New York Heart Association class ≥II) were predictive of increased mortality but not of SCD, suggesting a potential arrhythmic cause behind SCD."

Supports separating the arrhythmic route to sudden death from the heart-failure route to overall mortality; the inference is the authors' own and is stated as a suggestion, hence PARTIAL.

Chronic hypoxaemia and secondary erythrocytosis

Sustained arterial desaturation drives renal erythropoietin release and an appropriate compensatory rise in red cell mass. The rise is adaptive, not pathological in itself, and the historical practice of routine venesection to lower it is now recognised as harmful because it induces iron deficiency. Iron-deficient erythrocytes are less deformable, and iron deficiency, not haematocrit, is what tracks with symptoms and stroke risk.

Downstream

Hyperviscosity and haemostatic derangement Raised red cell mass increases whole-blood viscosity, though the correlation with symptoms is weaker than historically assumed.

Show evidence (2 references)

PMID:39711759 SUPPORT Human Clinical

"While this does occur in the context of cyanosis and secondary erythrocytosis, there is a tenuous correlation between hematocrit and viscosity, iron deficiency, or a patient's severity or frequency of symptoms"

Records the weak link between haematocrit and symptoms, which is the evidence base for abandoning haematocrit-triggered venesection.

PMID:9556469 SUPPORT Human Clinical

"Erythrocytosis is present in most patients, but excessive phlebotomy may cause microcytosis and exacerbate the symptoms of hyperviscosity."

States both that erythrocytosis is near-universal and that over-treating it with phlebotomy is counterproductive.

Hyperviscosity and haemostatic derangement

The haematologic consequence is bidirectional and awkward to manage: patients carry both a thrombotic tendency (in situ pulmonary artery thrombosis, paradoxical embolism) and a bleeding diathesis (haemoptysis, mucosal bleeding, perioperative haemorrhage). Pulmonary artery thrombosis in this disease tracks with biventricular dysfunction and slow pulmonary flow rather than with haematocrit or clotting-factor abnormalities, which argues for stasis rather than hypercoagulability as its proximate cause.

Downstream

Multisystem complications of chronic cyanosis The combined thrombotic and haemorrhagic tendency contributes to stroke, haemoptysis, and bleeding complications.

Show evidence (3 references)

PMID:9556469 SUPPORT Human Clinical

"The hemostatic changes associated with the syndrome may lead to thromboembolic events, cerebrovascular complications, or the hyperviscosity syndrome."

Establishes the haemostatic derangement and its thromboembolic and cerebrovascular consequences.

PMID:17692749 SUPPORT Human Clinical

"These patients were older (p = 0.032), but did not differ in oxygen saturation, hemoglobin, or hematocrit from those without thrombus."

Argues against erythrocytosis as the driver of pulmonary artery thrombosis, since thrombus-positive and thrombus-negative patients had indistinguishable haemoglobin and haematocrit.

PMID:17692749 SUPPORT Human Clinical

"Those with thrombus also had a larger main pulmonary artery diameter (48 +/- 14 mm vs. 38 +/- 9 mm, p = 0.007) and a lower peak systolic velocity in the pulmonary artery (p = 0.003)."

Identifies a dilated main pulmonary artery and slow pulmonary arterial flow, rather than a clotting abnormality, as the correlates of thrombus.

Loss of pulmonary filtration of venous emboli

With a right-to-left shunt the pulmonary capillary bed no longer filters the venous return, so thrombi and septic emboli pass directly into the systemic arterial circulation. This is the mechanism behind paradoxical embolic stroke and behind cerebral abscess, and it is why meticulous air-filtering of intravenous lines and endocarditis prophylaxis matter more here than in an acyanotic patient.

Downstream

Multisystem complications of chronic cyanosis Unfiltered emboli reaching the systemic circulation produce stroke and brain abscess.

Show evidence (1 reference)

PMID:9556469 SUPPORT Human Clinical

"The hemostatic changes associated with the syndrome may lead to thromboembolic events, cerebrovascular complications, or the hyperviscosity syndrome."

Documents the cerebrovascular consequence; the review attributes it to haemostatic change, so the loss-of-filtration route specifically is curated as PARTIAL rather than SUPPORT.

Multisystem complications of chronic cyanosis

Beyond the heart and lungs, sustained cyanosis and high red cell turnover produce a recognisable multiorgan burden: hyperuricaemia and gout, pigment cholelithiasis from chronic hyperbilirubinaemia, renal impairment with proteinuria, hypertrophic osteoarthropathy, and neurologic events. These are what make Eisenmenger syndrome a systemic disease rather than a cardiopulmonary one.

Show evidence (2 references)

PMID:9556469 SUPPORT Human Clinical

"Other complications associated with the Eisenmenger syndrome include hemoptysis, gout, cholelithiasis, hypertrophic osteoarthropathy, and decreased renal function."

Enumerates the multisystem complication set curated in this node.

PMID:35331414 SUPPORT Human Clinical

"remains a complex clinical entity with multisystem involvement, including secondary erythrocytosis, increased thrombotic and bleeding diathesis, high arrhythmogenic risk, progressive heart failure, and premature death"

State-of-the-art review characterising the disease as multisystem, with the specific domains listed.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

17

Blood 1

Iron deficiency Iron deficiency anemia HP:0001891

Show evidence (1 reference)

PMID:20580108 SUPPORT Human Clinical

"Iron deficiency is common in cyanotic congenital heart disease (CHD) and results in reduced exercise tolerance."

Establishes iron deficiency as common in this population and functionally consequential.

Cardiovascular 5

Pulmonary arterial hypertension OBLIGATE HP:0002092

Show evidence (1 reference)

PMID:39711759 SUPPORT Human Clinical

"Eisenmenger syndrome (ES) is defined as pulmonary hypertension due to a high pulmonary vascular resistance with reversed or bidirectional shunt"

Pulmonary hypertension is part of the operational definition, hence OBLIGATE.

Stroke HP:0001297

Show evidence (1 reference)

PMID:9556469 SUPPORT Human Clinical

"The hemostatic changes associated with the syndrome may lead to thromboembolic events, cerebrovascular complications, or the hyperviscosity syndrome."

Documents cerebrovascular complications as a recognised consequence.

Atrial fibrillation HP:0005110

Show evidence (1 reference)

PMID:32174228 SUPPORT Human Clinical

"Atrial fibrillation (11.45-fold increased risk; P<0.001) and QRS duration ≥120 ms (2.06-fold increased risk; P=0.034) remained significant predictors of SCD in the multivariate analysis"

Quantifies the sudden-death risk conferred by atrial fibrillation in 246 patients.

Syncope OCCASIONAL HP:0001279

Show evidence (2 references)

PMID:32174228 SUPPORT Human Clinical

"A history of syncope was documented in 20 (8.1%) patients."

Quantifies syncope at 8.1% of a 246-patient cohort, supporting an OCCASIONAL band.

PMID:32174228 REFUTE Human Clinical

"there was no significant association between the rare presence of coronary artery stenosis (including one case of extrinsic compression of the left main coronary artery requiring stenting), prior syncope, thromboembolism, cerebrovascular accident, phlebotomy or hemoptysis and SCD, cardiac..."

Argues against the common claim that syncope is a validated prognostic predictor in this disease, which is why the description states the caveat explicitly.

Sudden cardiac death HP:0001645

Show evidence (2 references)

PMID:35331414 SUPPORT Human Clinical

"high arrhythmogenic risk, progressive heart failure, and premature death"

Establishes high arrhythmogenic risk and premature death; the abstract does not separately quantify sudden death, so this is PARTIAL.

PMID:32690623 SUPPORT Human Clinical

"Progressive heart failure, infectious diseases and sudden cardiac death comprise the main causes of death in patients with ES."

Names sudden cardiac death among the three main causes of death.

Digestive 1

Cholelithiasis HP:0001081

Show evidence (1 reference)

PMID:9556469 SUPPORT Human Clinical

"Other complications associated with the Eisenmenger syndrome include hemoptysis, gout, cholelithiasis, hypertrophic osteoarthropathy, and decreased renal function."

Lists cholelithiasis among the recognised complications.

Genitourinary 1

Renal impairment Proteinuria HP:0000093

Show evidence (2 references)

PMID:39711759 SUPPORT Human Clinical

"Albuminuria is also highly prevalent with ES and other cyanotic CHD, with a prevalence upwards of 60 %"

Quantifies albuminuria prevalence above 60% in this population.

PMID:9556469 SUPPORT Human Clinical

"hemoptysis, gout, cholelithiasis, hypertrophic osteoarthropathy, and decreased renal function"

Independent listing of decreased renal function among the syndrome's complications.

Limbs 1

Digital clubbing HP:0001217

Show evidence (1 reference)

PMID:35331414 SUPPORT Human Clinical

"remains a complex clinical entity with multisystem involvement, including secondary erythrocytosis, increased thrombotic and bleeding diathesis, high arrhythmogenic risk, progressive heart failure, and premature death"

The state-of-the-art review characterises the multisystem cyanotic phenotype of which clubbing forms part; the abstract does not name clubbing itself, so this is curated as PARTIAL.

Musculoskeletal 1

Gout HP:0001997

Show evidence (1 reference)

PMID:9556469 SUPPORT Human Clinical

"Other complications associated with the Eisenmenger syndrome include hemoptysis, gout, cholelithiasis, hypertrophic osteoarthropathy, and decreased renal function."

Lists gout among the recognised complications.

Respiratory 1

Haemoptysis Hemoptysis HP:0002105

Show evidence (2 references)

PMID:9556469 SUPPORT Human Clinical

"Other complications associated with the Eisenmenger syndrome include hemoptysis, gout, cholelithiasis, hypertrophic osteoarthropathy, and decreased renal function."

Lists haemoptysis among the recognised complications.

PMID:39711759 SUPPORT Human Clinical

"hemoptysis has decreased significantly as the cause of death, from 3rd most common to 5th most common"

Quantifies the shift in haemoptysis as a terminal event between the pre- and post-drug-therapy eras.

Constitutional 2

Exercise intolerance VERY_FREQUENT HP:0003546

Show evidence (1 reference)

PMID:20439122 SUPPORT Human Clinical

"Exercise performance and quality of life is more impaired in Eisenmenger syndrome than in complex cyanotic congenital heart disease with pulmonary stenosis"

Comparative study establishing that exercise impairment in this disease exceeds that of other cyanotic congenital heart disease.

Fatigue HP:0012378

Show evidence (1 reference)

PMID:32174228 SUPPORT Human Clinical

"Clinical heart failure symptoms, increased risk of arrhythmias, syncope, sudden death, as well as complex hematologic, thrombotic, hemorrhagic, pulmonary, and infectious complications are all recognized sequelae of Eisenmenger syndrome."

Places clinical heart failure symptoms, of which fatigue is the cardinal one, among the recognised sequelae; the source does not name fatigue itself, hence PARTIAL.

Other 4

Central cyanosis VERY_FREQUENT HP:0034032

Show evidence (1 reference)

PMID:32690623 SUPPORT Human Clinical

"Central cyanosis is the primary clinical manifestation leading to secondary erythrocytosis and various multiorgan complications that increase morbidity and affect quality of life."

Names central cyanosis the primary clinical manifestation, supporting a near-universal frequency band.

Secondary erythrocytosis VERY_FREQUENT Increased hematocrit HP:0001899

Show evidence (1 reference)

PMID:9556469 SUPPORT Human Clinical

"Erythrocytosis is present in most patients"

Directly supports a very frequent band.

Exertional dyspnoea Exertional dyspnea HP:0002875

Show evidence (1 reference)

PMID:24012036 SUPPORT Human Clinical

"Eighteen consecutive patients with ES and exertional dyspnea according to the World Health Organization functional class III or IV were prospectively recruited."

Exertional dyspnoea used as the defining clinical entry criterion for an Eisenmenger trial cohort.

Right ventricular failure HP:0001708

Show evidence (1 reference)

PMID:39711759 SUPPORT Human Clinical

"in contemporary series, the most common cause of mortality remains right heart failure, unchanged from the pre-DTT era"

Establishes right heart failure as the leading terminal event.

🧬

Genetic Associations

4

BMPR2

Gene: BMPR2 hgnc:1078 relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

Show evidence (2 references)

PMID:27002414 SUPPORT Human Clinical

"Genetic predisposing factor may be an important component in the process of development of PVD in CHD patients."

The study's own conclusion, framed as predisposition rather than causation.

PMID:27002414 SUPPORT Human Clinical

"A significant higher BMPR2 mutation rate (12.6%) was found in repaired CHD-PVD (P=0.010). BMPR2 mutations in CHD-PVD patients were identified in different clinical phenotypes. Missense mutation of BMPR2 is the dominant mutation type."

Shows the enrichment concentrating in repaired patients, and identifies missense as the dominant variant class.

ACVRL1

Gene: ACVRL1 hgnc:175 relationship_type: UNKNOWN variant_origin: GERMLINE

ENG

Gene: ENG hgnc:3349 relationship_type: UNKNOWN variant_origin: GERMLINE

Trisomy 21

relationship_type: RISK_FACTOR variant_origin: GERMLINE

Show evidence (2 references)

PMID:27325590 SUPPORT Human Clinical

"the likelihood of developing ES decreased over time (53% birth cohort during 1950s/1960s vs 0.5% birth cohort during 2000-2009, p<0.0001)"

German National Register data on 894 Down syndrome patients with post-tricuspid shunts.

PMID:27325590 SUPPORT Human Clinical

"Patients with ES had a significantly worse survival compared with those without ES (HR 18.1; 95% CI 7.2 to 45.4; p<0.0001)."

Quantifies the survival cost of developing Eisenmenger syndrome within the Down syndrome congenital heart disease population.

💊

Medical Actions

5

Endothelin receptor antagonist therapy

Action: Pharmacotherapy NCIT:C15986

Agent: bosentan CHEBI:51450

Bosentan is the first-line pulmonary vasodilator and the only agent tested against placebo in a dedicated Eisenmenger randomised trial. BREATHE-5 showed it lowered pulmonary vascular resistance and mean pulmonary artery pressure and increased walk distance without worsening systemic oxygen saturation, which had been the theoretical safety concern, and the open-label extension showed the gain was sustained to 40 weeks.

Mechanism Target:

INHIBITS Increased pulmonary vascular resistance — Blocking endothelin receptors relieves the endothelin-driven component of vasoconstriction and proliferation, lowering pulmonary vascular resistance.

Show evidence (1 reference)

PMID:16801459 SUPPORT Human Clinical

"Compared with placebo, bosentan reduced pulmonary vascular resistance index (-472.0 dyne.s.cm(-5); P=0.0383). The mean pulmonary arterial pressure decreased (-5.5 mm Hg; P=0.0363), and the exercise capacity increased (53.1 m; P=0.0079)."

Placebo-controlled demonstration that endothelin blockade lowers pulmonary vascular resistance in this disease.

Target Phenotypes: Pulmonary arterial hypertension HP:0002092 Exercise intolerance HP:0003546

Show evidence (4 references)

PMID:16801459 SUPPORT Human Clinical

"In this first placebo-controlled trial in patients with Eisenmenger syndrome, bosentan was well tolerated and improved exercise capacity and hemodynamics without compromising peripheral oxygen saturation."

The pivotal randomised trial conclusion, addressing both efficacy and the shunt-worsening safety concern.

PMID:17658633 SUPPORT Human Clinical

"At week 24, the 6-minute walk distance (mean+/-SE) increased from OLE baseline for the ex-placebo (+33.2+/-23.9 m) and ex-bosentan group (+6.7+/-10.0 m)."

Open-label extension showing the walk-distance gain is maintained and extended out to 40 weeks of exposure.

PMID:27054605 SUPPORT Human Clinical

"Advanced therapy with pulmonary vasodilators has become part of the standard treatment, offering long-term benefits on exercise capacity, clinical symptoms, and possibly survival."

Systematic review establishing pulmonary vasodilators as standard treatment, while hedging the survival claim as only possible, which is why survival benefit is not asserted here.

+ 1 more reference

Phosphodiesterase-5 inhibitor therapy

Action: Pharmacotherapy NCIT:C15986

Agent: sildenafil CHEBI:9139

Sildenafil and tadalafil potentiate nitric-oxide-mediated pulmonary vasodilation, the arm of endothelial function that is depressed in this disease. Used as add-on to an endothelin antagonist or, in some settings, as monotherapy. Added to bosentan, sildenafil did not further improve walk distance but did raise resting oxygen saturation, an honest split result worth recording.

Mechanism Target:

RESTORES Shear-stress-mediated pulmonary endothelial dysfunction — Inhibiting phosphodiesterase-5 preserves cyclic GMP downstream of nitric oxide, compensating pharmacologically for the depressed endothelial nitric oxide arm.

Show evidence (1 reference)

PMID:20202971 SUPPORT Human Clinical

"Adding sildenafil to bosentan did not improve the 6 MWD significantly (21 vs. 8 m, P = 0.48), but increased saturation at rest (2.9 vs. -1.8%, P < 0.01)."

The saturation gain is consistent with improved pulmonary vasodilation, but the absence of a walk-distance effect means the mechanism claim is supported only partially.

Target Phenotypes: Pulmonary arterial hypertension HP:0002092

Show evidence (2 references)

PMID:20202971 SUPPORT Human Clinical

"In Eisenmenger syndrome, treatment with bosentan significantly improved walking distance, pulmonary blood flow, and PVR. Adding sildenafil to bosentan did not significantly improve walking distance but did increase saturation at rest."

Randomised cross-over trial in 21 patients giving a mixed result for add-on sildenafil, which is why the entry does not claim unqualified benefit.

PMID:20304507 SUPPORT Human Clinical

"Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy"

Independent report of functional and quality-of-life benefit from sildenafil in this population.

Prostanoid therapy

Action: Pharmacotherapy NCIT:C15986

Agent: iloprost CHEBI:63916

Inhaled iloprost and parenteral prostacyclin analogues replace the deficient prostacyclin arm of endothelial signalling. In the EIGER study inhaled iloprost improved walk distance, quality of life, and right ventricular performance, notably without changing pulmonary artery pressure or resistance, which suggests the functional gain is not purely haemodynamic.

Target Phenotypes: Exercise intolerance HP:0003546

Show evidence (2 references)

PMID:24012036 SUPPORT Human Clinical

"After 24 weeks of iloprost therapy, 6-minute walk test distance significantly increased (289.1 ± 76.9 to 369.5 ± 93.4 m, p = 0.032)"

Prospective study showing a substantial walk-distance gain with inhaled iloprost.

PMID:24012036 REFUTE Human Clinical

"Pulmonary arterial pressure and pulmonary vascular resistance did not improve with iloprost therapy."

Argues against a haemodynamic mechanism for the observed functional benefit, and is curated so the treatment is not presented as resistance-lowering.

Iron replacement therapy

Action: Pharmacotherapy NCIT:C15986

Agent: iron(2+) CHEBI:29033

Oral or intravenous iron corrects the iron deficiency that is common in cyanotic congenital heart disease, improving exercise capacity and quality of life. It is the modern replacement for the discredited practice of routine venesection, and it raises rather than lowers haemoglobin.

Target Phenotypes: Iron deficiency anemia HP:0001891 Exercise intolerance HP:0003546

Show evidence (2 references)

PMID:20580108 SUPPORT Human Clinical

"Significant improvements were also detected in the total CAMPHOR score (20.7 ± 10.9 to 16.2 ± 10.4, p=0.001) and 6MWT distance (371.7 ± 84.7 m to 402.8.0±74.9m, p=0.001)."

Prospective study showing quality-of-life and walk-distance gains from iron replacement.

PMID:9556469 SUPPORT Human Clinical

"Erythrocytosis is present in most patients, but excessive phlebotomy may cause microcytosis and exacerbate the symptoms of hyperviscosity."

Supports the accompanying caution against venesection, which causes the microcytosis that iron replacement is given to reverse.

Heart-lung or bilateral lung transplantation

Action: organ transplantation Ontology label: Organ Transplantation NCIT:C15289

The only intervention that alters the underlying disease rather than its symptoms. Strategy depends on the defect: for atrial septal defects, bilateral lung transplantation with concurrent defect repair gives outcomes at least as good as combined heart-lung transplantation, whereas ventricular septal defect disease has historically favoured heart-lung. Perioperative bleeding risk is elevated by the haemostatic derangement.

Target Phenotypes: Right ventricular failure HP:0001708

Show evidence (4 references)

PMID:34112578 SUPPORT Human Clinical

"LTx shows superior survival outcomes in the current era for ES ASD patients, and equivalent outcomes for ES-VSD."

ISHLT and OPTN registry analysis establishing that the optimal transplant strategy differs by underlying defect.

PMID:34112578 SUPPORT Human Clinical

"Compared to LTx for other indications, the odds of transplantation were significantly less for both ES-ASD"

Records that Eisenmenger patients are markedly less likely to actually reach transplantation than other lung transplant candidates, which qualifies how available this option is in practice.

PMID:32565271 SUPPORT Human Clinical

"During the study period, 442 adults with ES underwent thoracic transplantation (316 HLTs and 126 BLTs). Following BLT, overall survival 1, 5, and 10 years' posttransplant was 63.1%, 38.5%, and 30.2%, respectively."

United Network for Organ Sharing analysis of 442 Eisenmenger transplants giving absolute survival figures for the bilateral lung strategy, and independently addressing which strategy suits which defect.

+ 1 more reference

🔬

Biochemical Markers

1

Brain natriuretic peptide (INCREASED)

Show evidence (2 references)

PMID:40204597 SUPPORT Human Clinical

"Several risk factors have been identified as independent predictors in Eisenmenger syndrome, including the 6-minute walk distance, echocardiographic markers and serum brain natriuretic peptide."

Names serum brain natriuretic peptide among the independent prognostic predictors.

PMID:32690623 SUPPORT Human Clinical

"Impaired exercise tolerance, decreased arterial oxygen saturation, iron deficiency, pre-tricuspid shunts, arrhythmias, increased brain natriuretic peptide, echocardiographic indices of right ventricular dysfunction and hospitalisation for heart failure predict mortality."

Independent listing of raised brain natriuretic peptide among the mortality predictors, alongside the arrhythmia and iron-deficiency features curated elsewhere in this entry.

🔬

Diagnosis

4

Transthoracic echocardiography

The mainstay non-invasive test. It identifies the underlying defect, demonstrates the direction of shunting on colour Doppler (right-to-left or bidirectional), estimates pulmonary artery pressure, and assesses right ventricular size and function. A diagnostic pitfall worth knowing: the murmur may be quiet or absent, because equalised ventricular pressures abolish the turbulent gradient across the defect.

echocardiography NCIT:C16525

Show evidence (1 reference)

PMID:27002414 SUPPORT Human Clinical

"PAH was diagnosed by heart catheterization at rest after CHD was first recognized by echocardiography."

Documents the standard diagnostic sequence, in which echocardiography identifies the congenital defect and catheterisation then confirms the pulmonary hypertension.

Right heart catheterisation

The confirmatory gold standard, giving direct measurement of pulmonary artery pressure, pulmonary vascular resistance, and oximetry at each chamber, and where relevant vasoreactivity testing to judge whether any operability remains. It is the test that distinguishes still-correctable pulmonary arterial hypertension associated with congenital heart disease from established, inoperable Eisenmenger physiology.

right heart catheterization NCIT:C80411

Show evidence (2 references)

PMID:27002414 SUPPORT Human Clinical

"PVD was defined as a pulmonary vascular resistance (PVR) more than 3 Wood units."

Shows catheter-measured pulmonary vascular resistance being used as the defining diagnostic criterion for pulmonary vascular disease in congenital heart disease.

PMID:16801459 SUPPORT Human Clinical

"Hemodynamics were assessed by right- and left-heart catheterization."

Catheterisation used as the reference haemodynamic assessment in the pivotal Eisenmenger trial.

Pulse oximetry

Resting and exertional oxygen saturation quantifies the right-to-left shunt burden and is itself prognostic. Because pulmonary vasodilators could in principle worsen shunting by dropping systemic resistance, saturation is also the key safety measurement when starting these drugs.

pulse oximetry NCIT:C38085

Show evidence (1 reference)

PMID:16801459 SUPPORT Human Clinical

"The placebo-corrected effect on systemic pulse oximetry was 1.0% (95% confidence interval, -0.7 to 2.8), demonstrating that bosentan did not worsen oxygen saturation."

Pulse oximetry used as the primary safety endpoint, testing the theoretical concern that a vasodilator might worsen right-to-left shunting.

Iron studies and full blood count

Haemoglobin, haematocrit, ferritin, and transferrin saturation characterise the secondary erythrocytosis and, more importantly, detect the iron deficiency that is treatable and functionally consequential. Interpreting haemoglobin without iron indices is what historically led to inappropriate venesection.

blood cell count NCIT:C28133

Show evidence (1 reference)

PMID:20580108 SUPPORT Human Clinical

"After 3 months of treatment, hemoglobin (19.0 ± 2.9 g/dL to 20.4 ± 2.7 g/dL, p<0.001), ferritin (13.3 ± 4.7 μg/L to 54.1 ± 24.2 μg/L, p<0.001) and transferrin saturation (17.8 ± 9.6% to 34.8 ± 23.4%, p<0.001) significantly increased."

Shows ferritin and transferrin saturation being used to identify and track the iron deficiency that a haemoglobin measurement alone would conceal.

📈

Progression

2

Latent left-to-right shunt phase

An initially asymptomatic or minimally symptomatic period during which the shunt is left-to-right and pulmonary vascular resistance is normal or only mildly elevated. Repair during this window prevents the syndrome entirely, and the practical target is intervention within the first year or two of life. Post-tricuspid lesions may traverse this phase within infancy; pre-tricuspid atrial defects may take three or four decades.

Show evidence (1 reference)

PMID:27325590 SUPPORT Human Clinical

"The likelihood of being treated interventionally or surgically before the age of 1 year increased significantly over time. In parallel, the likelihood of developing ES decreased over time (53% birth cohort during 1950s/1960s vs 0.5% birth cohort during 2000-2009, p<0.0001)."

Demonstrates that operating within the first year of life during the latent phase reduces progression from 53% to 0.5%.

Established Eisenmenger physiology

Once pulmonary vascular resistance is fixed and the shunt has reversed, the disease is chronic and progressive, punctuated by complications rather than following a smooth decline. Defect closure is now contraindicated. Survival is substantially reduced: 10-year survival is 57% overall and 34% among patients never given pulmonary vasodilator therapy, and the leading terminal event is right heart failure.

Show evidence (2 references)

PMID:39711759 SUPPORT Human Clinical

"Once these biases were accounted for, 10-year survival for contemporary patients with ES was 57 % in the overall cohort and 34 % in patients naïve to disease targeting therapy (DTT)"

Gives the contemporary 10-year survival figures, corrected for the survivorship bias that inflated earlier estimates.

PMID:25099652 SUPPORT Human Clinical

"After accounting for this effect we found high standardised mortality ratios, a 10-year mortality rate approaching 30-40% and no evidence of superior survival prospects of current era patients compared with those seen in the 1970s, 1980s and 1990s."

Systematic review of 1131 patients correcting for immortal time bias, and finding no survival improvement in treatment-naive patients across four decades.

📊

Prevalence

2

Adults with congenital heart disease, contemporary registries in high-resource settings

Point Prevalence >1 in 1,000

Between 1% and 5.7% of contemporary congenital heart disease registry populations, down from the 17.5% Paul Wood described in 1958. The denominator here is patients with congenital heart disease, not the general population, so the prevalence class reflects frequency within that population rather than population prevalence. The decline is attributable to early surgical repair and is not seen in regions with limited access to paediatric cardiac surgery.

Show evidence (2 references)

PMID:39711759 SUPPORT Human Clinical

"to between 1 and 5.7 % in more contemporary registries"

Gives the contemporary registry range. The same sentence records the historical 17.5% figure Paul Wood described in 1958, but that clause carries an inline citation marker that the reference validator strips, so the quoted portion is the bracket-free tail.

PMID:39711759 SUPPORT Human Clinical

"However, a similar trend may not be seen in patients from regions with less robust access to medical resources"

Records that the decline is confined to high-resource settings, so the contemporary figure should not be generalised globally.

Down syndrome with a post-tricuspid shunt lesion, German National Register

Period Prevalence >1 in 1,000

53% of the 1950s-1960s birth cohort developed Eisenmenger syndrome, versus 0.5% of the 2000-2009 birth cohort, in 894 patients with Down syndrome and a post-tricuspid shunt. The two figures are the same population separated only by access to early surgery.

Show evidence (1 reference)

PMID:27325590 SUPPORT Human Clinical

"Out of 1549 patients with DS with congenital heart disease in the National Register for Congenital Heart Defects, 894 patients (55% female, mean age 17.5 years) had a post-tricuspid shunt lesion"

Defines the register cohort from which the birth-cohort progression rates are drawn.

⚖️

Clinical Burden

High

A lifelong, progressive, multisystem disease with 10-year survival of 57% overall and 34% without pulmonary vasodilator therapy, no curative option short of transplantation, and an absolute contraindication to pregnancy in a population that reaches childbearing age. Exercise capacity and quality of life are worse than in other complex cyanotic congenital heart disease.

Right heart failure is the leading cause of death, with sudden cardiac death and infection next. Pregnancy carries very high maternal mortality and is contraindicated. Non-cardiac surgery is also high-risk. Pulmonary vasodilator therapy has improved functional capacity and quality of life, but a systematic review correcting for immortal time bias found no improvement in survival among treatment-naive patients across four decades, so the burden should not be read as historical.

Show evidence (7 references)

PMID:39711759 SUPPORT Human Clinical

"Once these biases were accounted for, 10-year survival for contemporary patients with ES was 57 % in the overall cohort and 34 % in patients naïve to disease targeting therapy (DTT)"

Contemporary bias-corrected survival figures.

PMID:9556469 SUPPORT Human Clinical

"Pregnancy or noncardiac surgery is associated with a high mortality rate in patients with the Eisenmenger syndrome."

Establishes both pregnancy and non-cardiac surgery as high-mortality exposures.

PMID:34616573 SUPPORT Human Clinical

"Pregnancy complications found include preterm birth (78%), low birthweight (94%), intrauterine growth restriction (55%), oligohydramnios (16%), severe preeclampsia (33%), and placenta previa (5.5%)."

Retrospective cohort of 18 pregnancies quantifying the obstetric complication burden.

+ 4 more references

🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Eisenmenger Syndrome:

Idiopathic pulmonary arterial hypertension MONDO:0001999

Overlapping Features Shares the pulmonary vascular lesion but has no structural shunt. The distinction is not academic: without a decompressing shunt the right ventricle bears the full afterload, so idiopathic disease carries worse haemodynamics and shorter survival at equivalent pulmonary pressures, and the treatment goal is unequivocally to lower pulmonary vascular resistance rather than to preserve a protective shunt.

Distinguishing Features

No structural intracardiac or aortopulmonary communication
No right-to-left shunt, so no central cyanosis from shunting and no secondary erythrocytosis
Worse haemodynamics and survival at comparable pulmonary artery pressures
Defect closure is not a consideration; there is no shunt to preserve or close

Show evidence (1 reference)

PMID:19245962 SUPPORT Human Clinical

"Although ES shares similar morphological findings with idiopathic PAH, clinical differences exist between the 2 etiologies. Adults with ES exhibit increased survival and more favorable hemodynamics than those with idiopathic PAH."

States both the shared pulmonary vascular morphology and the divergent clinical course that separates the two entities.

Operable pulmonary arterial hypertension associated with congenital heart disease

Overlapping Features The same disease at an earlier point on its trajectory, before pulmonary vascular resistance becomes fixed and the shunt reverses. This is the single most consequential distinction in the entry, because the two are managed in opposite directions: the operable patient should have the defect closed, and the Eisenmenger patient must not. Right heart catheterisation with vasoreactivity testing is what separates them.

Distinguishing Features

Shunt still predominantly left-to-right, without resting cyanosis
Pulmonary vascular resistance not yet fixed, and may fall on vasoreactivity testing
Defect closure indicated rather than contraindicated
Secondary erythrocytosis and the multisystem cyanotic complications are absent

Show evidence (2 references)

PMID:33853494 SUPPORT Human Clinical

"Once Eisenmenger syndrome develops, shunt closure should be avoided."

States the management divergence that makes this differential decisive.

PMID:31120797 SUPPORT Human Clinical

"PAH-CHD describes a wide spectrum of conditions, of which ES is the archetype."

Positions Eisenmenger syndrome as the severe end of a spectrum, the earlier parts of which remain operable.

📊

Related Datasets

1

Remodeling of active endothelial enhancers is associated with aberrant gene-regulatory networks in pulmonary arterial hypertension [ChIP-seq] geo:GSE126322

Chromatin profiling (H3K27ac, H3K4me1, H3K4me3 ChIP-seq) of pulmonary arterial endothelial cells extracted from the lungs of 10 patients with pulmonary arterial hypertension and 9 controls, showing large-scale remodeling of the active enhancer landscape while promoters and gene expression were unchanged.

human CHIP SEQ n=55 ChIP-seq of H3K27ac, H3K4me1 and H3K4me3

Conditions: pulmonary arterial hypertension control

PMID:32245974

Relevance triage, stated plainly: this dataset contains NO Eisenmenger syndrome and no congenital heart disease samples. Its cohort is pulmonary arterial hypertension generally. It is included solely because this entry declares `conforms_to` against `pulmonary_vascular_remodeling#Pulmonary Endothelial Dysfunction and Impaired BMP Signaling`, and this is primary human pulmonary artery endothelial cell data for exactly that conformed node; it cannot support any Eisenmenger-specific claim, and no evidence item cites it. No Eisenmenger-specific transcriptomic, epigenomic, or proteomic dataset exists in GEO. All 12 candidates surfaced by dataset discovery were gene-only matches on BMPR2 with no congenital-heart-disease content, so this is the closest mechanistically relevant primary dataset rather than a disease match.

🔬

Clinical Trials

2

NCT01743001 PHASE_III COMPLETED

MAESTRO. Multicentre, double-blind, randomised, placebo-controlled, parallel-group phase 3 trial of macitentan for exercise capacity in Eisenmenger syndrome. It is the largest randomised trial conducted specifically in this disease. This entry curates bosentan rather than macitentan as the endothelin antagonist with Eisenmenger-specific randomised support, because BREATHE-5 is the trial whose positive result is quotable from a cached abstract; no cached source in this entry reports the MAESTRO outcome, so none is asserted here.

Target Phenotypes: Exercise intolerance HP:0003546

Show evidence (1 reference)

clinicaltrials:NCT01743001 SUPPORT

"Clinical study to assess the efficacy, safety, and tolerability of macitentan in subjects with Eisenmenger Syndrome."

Registry record for the phase 3 macitentan exercise-capacity trial in Eisenmenger syndrome.

NCT01739400 PHASE_III COMPLETED

Long-term single-arm open-label extension of the MAESTRO protocol, assessing safety, tolerability and efficacy of macitentan in Eisenmenger syndrome beyond the randomised period.

Target Phenotypes: Pulmonary arterial hypertension HP:0002092

Show evidence (1 reference)

clinicaltrials:NCT01739400 SUPPORT

"Long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of Eisenmenger syndrome."

Registry record for the open-label extension of the macitentan programme in Eisenmenger syndrome.

{ }

Source YAML

click to show

name: Eisenmenger Syndrome
creation_date: '2026-08-09T00:00:00Z'
category: Complex
description: >
  Eisenmenger syndrome is the terminal stage of an uncorrected congenital
  systemic-to-pulmonary shunt and the most advanced form of pulmonary arterial
  hypertension associated with congenital heart disease. A large, non-restrictive
  communication at atrial, ventricular, or aortopulmonary level exposes the pulmonary
  circulation to decades of high flow and, in post-tricuspid lesions, systemic pressure.
  Shear stress on the pulmonary endothelium is the leading proposed trigger for
  progressive obstructive pulmonary vascular remodeling, which raises pulmonary vascular
  resistance until it equals or exceeds systemic resistance and the shunt reverses to
  right-to-left or bidirectional. That reversal is the defining moment of Eisenmenger
  physiology and produces chronic arterial hypoxaemia, secondary erythrocytosis, and a
  multisystem disease with haematologic, neurologic, renal, and rheumatologic
  manifestations. A counterintuitive consequence follows: the same shunt that caused the
  disease now decompresses the pressure-loaded right ventricle, which is why patients
  survive longer than those with idiopathic pulmonary arterial hypertension at comparable
  haemodynamics, and why closing the defect once Eisenmenger physiology is established is
  contraindicated rather than curative.
disease_term:
  preferred_term: Eisenmenger syndrome
  term:
    id: MONDO:0019944
    label: Eisenmenger syndrome
parents:
- Congenital heart defect
- Pulmonary arterial hypertension
synonyms:
- Eisenmenger complex
- Eisenmenger reaction
- Eisenmenger physiology
- Pulmonary arterial hypertension associated with congenital heart disease
pathophysiology:
- name: Uncorrected non-restrictive systemic-to-pulmonary shunt
  description: >
    The initiating lesion is a large congenital communication at the atrial, ventricular,
    or aortopulmonary level that is never closed, or is closed too late. Shunt level
    governs risk: post-tricuspid defects (ventricular septal defect, patent ductus
    arteriosus, atrioventricular septal defect, truncus arteriosus) transmit systemic
    pressure as well as flow to the pulmonary bed and carry much the higher risk, whereas
    pre-tricuspid atrial-level defects transmit volume alone and progress far less often
    and far later. Trisomy 21 with a post-tricuspid lesion accelerates the whole sequence.
  biological_scale: ORGANISM
  role: trigger
  locations:
  - preferred_term: Heart
    term:
      id: UBERON:0000948
      label: heart
  downstream:
  - target: Shear-stress-mediated pulmonary endothelial dysfunction
    causal_link_type: DIRECT
    description: >
      Chronic high pulmonary blood flow imposes abnormal shear stress on the pulmonary
      arterial endothelium.
    evidence:
    - reference: PMID:39711759
      reference_title: "Update on Eisenmenger syndrome - Review of pathophysiology and recent progress in risk assessment and management."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The biological mechanisms are not fully understood, but a leading hypothesis is that increased shear stress on the pulmonary endothelium triggers pulmonary vascular remodeling, eventually resulting in irreversible pulmonary vascular disease"
      explanation: States the shear-stress trigger explicitly, and flags it as the leading hypothesis rather than settled mechanism.
  evidence:
  - reference: PMID:39711759
    reference_title: "Update on Eisenmenger syndrome - Review of pathophysiology and recent progress in risk assessment and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It develops in the presence of a non-restrictive communication at the aortopulmonary, ventricular, or atrial level."
    explanation: Defines the anatomic substrate and the three levels at which the communication may sit.
  - reference: PMID:27325590
    reference_title: "Eisenmenger syndrome and long-term survival in patients with Down syndrome and congenital heart disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The likelihood of being treated interventionally or surgically before the age of 1 year increased significantly over time. In parallel, the likelihood of developing ES decreased over time (53% birth cohort during 1950s/1960s vs 0.5% birth cohort during 2000-2009, p<0.0001)."
    explanation: German National Register data in 894 Down syndrome patients with post-tricuspid shunts, showing that leaving the shunt uncorrected is what produces the syndrome, and that early repair all but abolishes it.
- name: Shear-stress-mediated pulmonary endothelial dysfunction
  description: >
    Pulmonary arterial endothelial cells exposed to sustained abnormal shear stress lose
    homeostatic function, shifting the balance from vasodilation toward vasoconstriction
    and proliferation. Nitric oxide and prostacyclin production fall while endothelin-1
    rises. This is the same endothelial lesion that initiates idiopathic and heritable
    pulmonary arterial hypertension, reached here by a mechanical rather than a genetic
    route, which is why the three endothelium-directed drug classes developed for those
    diseases also work in Eisenmenger syndrome.
  biological_scale: CELLULAR
  conforms_to: "pulmonary_vascular_remodeling#Pulmonary Endothelial Dysfunction and Impaired BMP Signaling"
  locations:
  - preferred_term: Pulmonary artery
    term:
      id: UBERON:0002012
      label: pulmonary artery
  cell_types:
  - preferred_term: Pulmonary artery endothelial cell
    term:
      id: CL:1001568
      label: pulmonary artery endothelial cell
  biological_processes:
  - preferred_term: nitric oxide biosynthetic process
    term:
      id: GO:0006809
      label: nitric oxide biosynthetic process
    modifier: DECREASED
  downstream:
  - target: Pulmonary artery smooth muscle proliferation and vasoconstriction
    causal_link_type: DIRECT
    description: >
      Loss of endothelial vasodilator tone and excess endothelin-1 drive medial smooth
      muscle proliferation and sustained vasoconstriction.
    evidence:
    - reference: PMID:16801459
      reference_title: "Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Because Eisenmenger syndrome is associated with increased endothelin expression, patients may benefit from endothelin receptor antagonism."
      explanation: Endothelial endothelin excess is the signal proposed to act on the medial compartment; the abstract states the association and therapeutic rationale rather than demonstrating the cellular step, hence PARTIAL.
  evidence:
  - reference: PMID:16801459
    reference_title: "Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Because Eisenmenger syndrome is associated with increased endothelin expression, patients may benefit from endothelin receptor antagonism."
    explanation: Establishes increased endothelin expression as a feature of the syndrome, which is the rationale on which the endothelin-antagonist trial was built.
  - reference: PMID:19245962
    reference_title: "Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although ES shares similar morphological findings with idiopathic PAH, clinical differences exist between the 2 etiologies."
    explanation: Supports the shared pulmonary vascular lesion that underlies module conformance, while flagging that the two diseases are not clinically equivalent.
- name: Pulmonary artery smooth muscle proliferation and vasoconstriction
  description: >
    Paracrine signals from the dysfunctional endothelium drive a pro-proliferative,
    anti-apoptotic switch in pulmonary artery smooth muscle cells together with sustained
    vasoconstriction, increasing medial cellularity. This is the amplifying step shared
    with all forms of pulmonary arterial hypertension.
  biological_scale: CELLULAR
  conforms_to: "pulmonary_vascular_remodeling#Pulmonary Artery Smooth Muscle Cell Proliferation and Vasoconstriction"
  cell_types:
  - preferred_term: Pulmonary artery smooth muscle cell
    term:
      id: CL:0002591
      label: smooth muscle cell of the pulmonary artery
  biological_processes:
  - preferred_term: smooth muscle cell proliferation
    term:
      id: GO:0048659
      label: smooth muscle cell proliferation
    modifier: INCREASED
  downstream:
  - target: Obstructive pulmonary vascular remodeling
    causal_link_type: DIRECT
    description: >
      Sustained medial proliferation progresses to fixed structural obstruction of the
      small pulmonary arteries.
    evidence:
    - reference: PMID:39711759
      reference_title: "Update on Eisenmenger syndrome - Review of pathophysiology and recent progress in risk assessment and management."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Longstanding left-to-right shunting associated with congenital heart disease (CHD) can ultimately lead to pulmonary vascular remodeling, pulmonary arterial hypertension, and shunt reversal, the hallmark feature of Eisenmenger Syndrome (ES)."
      explanation: Places pulmonary vascular remodeling in the causal chain downstream of chronic shunt flow; the cellular step from medial proliferation to fixed obstruction is inferred from the module rather than stated in this source.
  evidence:
  - reference: PMID:16801459
    reference_title: "Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Compared with placebo, bosentan reduced pulmonary vascular resistance index (-472.0 dyne.s.cm(-5); P=0.0383)."
    explanation: Pharmacologic reversal of part of the resistance by blocking endothelin signalling implies a component of ongoing endothelin-driven vasoconstriction and proliferation rather than purely fixed obstruction.
- name: Obstructive pulmonary vascular remodeling
  description: >
    Progressive structural obliteration of the small pulmonary arteries: medial
    hypertrophy, then intimal cellular proliferation and concentric fibrosis, then
    plexiform arteriopathy, the sequence graded histologically by Heath and Edwards. In
    situ thrombosis compounds the luminal loss. Once advanced, the lesion is irreversible,
    which is what converts a correctable congenital defect into an inoperable one.
  biological_scale: TISSUE
  conforms_to: "pulmonary_vascular_remodeling#Obstructive Pulmonary Vascular Remodeling"
  locations:
  - preferred_term: Pulmonary artery
    term:
      id: UBERON:0002012
      label: pulmonary artery
  biological_processes:
  - preferred_term: blood vessel remodeling
    term:
      id: GO:0001974
      label: blood vessel remodeling
    modifier: DYSREGULATED
  downstream:
  - target: Increased pulmonary vascular resistance
    causal_link_type: DIRECT
    description: >
      Loss of cross-sectional area in the small pulmonary arteries raises the resistance
      the right ventricle pumps against.
    evidence:
    - reference: PMID:39711759
      reference_title: "Update on Eisenmenger syndrome - Review of pathophysiology and recent progress in risk assessment and management."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Longstanding left-to-right shunting associated with congenital heart disease (CHD) can ultimately lead to pulmonary vascular remodeling, pulmonary arterial hypertension, and shunt reversal, the hallmark feature of Eisenmenger Syndrome (ES)."
      explanation: States the progression from pulmonary vascular remodeling to pulmonary arterial hypertension, the haemodynamic expression of raised resistance.
  evidence:
  - reference: PMID:39711759
    reference_title: "Update on Eisenmenger syndrome - Review of pathophysiology and recent progress in risk assessment and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Longstanding left-to-right shunting associated with congenital heart disease (CHD) can ultimately lead to pulmonary vascular remodeling, pulmonary arterial hypertension, and shunt reversal, the hallmark feature of Eisenmenger Syndrome (ES)."
    explanation: States the remodeling step and its position in the causal chain between the shunt and shunt reversal.
- name: Increased pulmonary vascular resistance
  description: >
    Fixed structural obstruction plus a residual vasoconstrictive component raise pulmonary
    vascular resistance toward and beyond systemic levels. The degree of elevation and its
    reversibility on vasoreactivity testing are what determine whether any operability
    window remains.
  biological_scale: ORGANISM
  conforms_to: "pulmonary_vascular_remodeling#Increased Pulmonary Vascular Resistance"
  downstream:
  - target: Shunt reversal to right-to-left or bidirectional flow
    causal_link_type: DIRECT
    description: >
      When pulmonary vascular resistance equals or exceeds systemic vascular resistance,
      the pressure gradient across the defect inverts.
    evidence:
    - reference: PMID:31120797
      reference_title: "Eisenmenger syndrome and other types of pulmonary arterial hypertension related to adult congenital heart disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "It is characterised by a severe rise in pulmonary vascular resistance resulting in shunt reversal and cyanosis."
      explanation: States the causal step from rising pulmonary vascular resistance to shunt reversal explicitly.
  - target: Pulmonary arterial hypertension with right ventricular pressure overload
    causal_link_type: DIRECT
    description: >
      The right ventricle faces a chronically elevated afterload.
    evidence:
    - reference: PMID:39711759
      reference_title: "Update on Eisenmenger syndrome - Review of pathophysiology and recent progress in risk assessment and management."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "in contemporary series, the most common cause of mortality remains right heart failure, unchanged from the pre-DTT era"
      explanation: Right heart failure dominating mortality is the clinical consequence of the chronic pressure overload; the source reports the outcome rather than measuring the afterload step, hence PARTIAL.
  evidence:
  - reference: PMID:31120797
    reference_title: "Eisenmenger syndrome and other types of pulmonary arterial hypertension related to adult congenital heart disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is characterised by a severe rise in pulmonary vascular resistance resulting in shunt reversal and cyanosis."
    explanation: Places the rise in pulmonary vascular resistance immediately upstream of shunt reversal and cyanosis.
- name: Shunt reversal to right-to-left or bidirectional flow
  description: >
    The defining event. Once pulmonary vascular resistance matches or exceeds systemic
    resistance, deoxygenated blood crosses the defect into the systemic circulation
    instead of the reverse, producing chronic arterial hypoxaemia and central cyanosis.
    This node is what distinguishes Eisenmenger syndrome from every other form of
    pulmonary arterial hypertension and from earlier, still-operable stages of
    pulmonary arterial hypertension associated with congenital heart disease; it is
    deliberately not mapped onto the `pulmonary_vascular_remodeling` module, which has no
    counterpart for it.
  biological_scale: ORGANISM
  downstream:
  - target: Chronic hypoxaemia and secondary erythrocytosis
    causal_link_type: DIRECT
    description: >
      Systemic delivery of deoxygenated blood lowers arterial oxygen saturation.
    evidence:
    - reference: PMID:32690623
      reference_title: "Eisenmenger syndrome: diagnosis, prognosis and clinical management."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Central cyanosis is the primary clinical manifestation leading to secondary erythrocytosis and various multiorgan complications that increase morbidity and affect quality of life."
      explanation: States the causal step from the cyanosis produced by shunt reversal to secondary erythrocytosis.
  - target: Right-to-left shunt as a protective right ventricular pop-off
    causal_link_type: DIRECT
    description: >
      The same reversed shunt that causes the hypoxaemia also unloads the pressurised
      right ventricle.
    evidence:
    - reference: PMID:19245962
      reference_title: "Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Adults with ES exhibit increased survival and more favorable hemodynamics than those with idiopathic PAH."
      explanation: The more favourable haemodynamics relative to idiopathic disease, which lacks any shunt, is the observable signature of the decompressing effect.
  - target: Loss of pulmonary filtration of venous emboli
    causal_link_type: DIRECT
    description: >
      Venous thrombi and septic emboli bypass the pulmonary capillary bed and enter the
      systemic arterial circulation directly.
    evidence:
    - reference: PMID:9556469
      reference_title: "The Eisenmenger syndrome in adults."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The hemostatic changes associated with the syndrome may lead to thromboembolic events, cerebrovascular complications, or the hyperviscosity syndrome."
      explanation: Documents thromboembolic and cerebrovascular events in the syndrome; the specific attribution to loss of pulmonary filtration is mechanistic inference, hence PARTIAL.
  evidence:
  - reference: PMID:39711759
    reference_title: "Update on Eisenmenger syndrome - Review of pathophysiology and recent progress in risk assessment and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Eisenmenger syndrome (ES) is defined as pulmonary hypertension due to a high pulmonary vascular resistance with reversed or bidirectional shunt"
    explanation: The operational definition of the syndrome, making shunt reversal the defining node rather than an incidental consequence.
  - reference: PMID:32690623
    reference_title: "Eisenmenger syndrome: diagnosis, prognosis and clinical management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Central cyanosis is the primary clinical manifestation leading to secondary erythrocytosis and various multiorgan complications that increase morbidity and affect quality of life."
    explanation: Connects the reversed shunt to cyanosis and onward to the multiorgan complication burden.
- name: Right-to-left shunt as a protective right ventricular pop-off
  description: >
    A genuinely counterintuitive node, and the reason management differs from every other
    severe pulmonary arterial hypertension. By venting the pressure-loaded right ventricle
    into the systemic circulation, the reversed shunt preserves cardiac output and defers
    right ventricular failure, so patients with Eisenmenger syndrome survive longer and
    have more favourable haemodynamics than adults with idiopathic pulmonary arterial
    hypertension at comparable pulmonary pressures. The therapeutic corollary is that
    closing the defect once the physiology is established removes the pop-off and
    precipitates right heart failure, which is why shunt closure is contraindicated rather
    than curative at this stage.
  biological_scale: ORGANISM
  evidence:
  - reference: PMID:19245962
    reference_title: "Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Adults with ES exhibit increased survival and more favorable hemodynamics than those with idiopathic PAH."
    explanation: The comparative survival advantage over idiopathic pulmonary arterial hypertension, which is the observable consequence of the decompressing shunt.
  - reference: PMID:33853494
    reference_title: "Preventing disease progression in Eisenmenger syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Once Eisenmenger syndrome develops, shunt closure should be avoided."
    explanation: The management corollary stated directly, namely that the defect must be left open once the physiology is established.
- name: Pulmonary arterial hypertension with right ventricular pressure overload
  description: >
    Sustained elevation of pulmonary arterial pressure imposes chronic pressure overload
    on the right ventricle, driving hypertrophy and ultimately maladaptive remodeling and
    failure. Right heart failure remains the leading cause of death in the modern
    drug-therapy era, unchanged from before it.
  biological_scale: ORGANISM
  conforms_to: "pulmonary_vascular_remodeling#Pulmonary Arterial Hypertension"
  locations:
  - preferred_term: Right ventricle
    term:
      id: UBERON:0002080
      label: heart right ventricle
  biological_processes:
  - preferred_term: cardiac muscle hypertrophy
    term:
      id: GO:0003300
      label: cardiac muscle hypertrophy
    modifier: INCREASED
  downstream:
  - target: Atrial arrhythmia and conduction system disease
    causal_link_type: DIRECT
    description: >
      Chronic right-sided pressure overload and atrial stretch create the arrhythmic and
      conduction-system substrate.
    evidence:
    - reference: PMID:32174228
      reference_title: "Determinants of Sudden Cardiac Death in Adult Patients With Eisenmenger Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Age, atrial fibrillation, prolonged QRS duration, complete heart block, right atrial enlargement, right bundle branch block, increased right atrial pressure, impaired biventricular function, and the presence of a pacemaker were associated with increased risk of SCD"
      explanation: Right atrial enlargement, raised right atrial pressure, and impaired ventricular function cluster with the arrhythmias in the same risk set, consistent with pressure overload generating the substrate; the association is cross-sectional, hence PARTIAL.
  evidence:
  - reference: PMID:39711759
    reference_title: "Update on Eisenmenger syndrome - Review of pathophysiology and recent progress in risk assessment and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "in contemporary series, the most common cause of mortality remains right heart failure, unchanged from the pre-DTT era"
    explanation: Establishes right heart failure as the dominant terminal event, and that modern drug therapy has not displaced it.
- name: Atrial arrhythmia and conduction system disease
  description: >
    Chronic right atrial stretch and right ventricular pressure overload generate an
    arrhythmic substrate: atrial fibrillation, prolonged QRS duration, complete heart
    block, and right bundle branch block are all associated with sudden cardiac death in
    this population, and atrial fibrillation is by some margin the strongest independent
    predictor. This is the proximate route to the sudden deaths that make up a large share
    of mortality, and it is separable from the progressive pump failure that kills the
    rest. Notably, advanced pulmonary vasodilator therapy was strongly protective against
    sudden death in the same analysis.
  biological_scale: ORGANISM
  locations:
  - preferred_term: Right atrium
    term:
      id: UBERON:0002078
      label: right cardiac atrium
  evidence:
  - reference: PMID:32174228
    reference_title: "Determinants of Sudden Cardiac Death in Adult Patients With Eisenmenger Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Atrial fibrillation (11.45-fold increased risk; P<0.001) and QRS duration ≥120 ms (2.06-fold increased risk; P=0.034) remained significant predictors of SCD in the multivariate analysis, whereas advanced pulmonary hypertension therapies were strongly protective against SCD (P<0.001)."
    explanation: Two-centre study of 246 patients identifying atrial fibrillation as the dominant independent predictor of sudden cardiac death, with pulmonary vasodilator therapy protective.
  - reference: PMID:32174228
    reference_title: "Determinants of Sudden Cardiac Death in Adult Patients With Eisenmenger Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Atrial arrhythmias, impaired ventricular function, and conduction system disease were associated with increased risk of SCD in this cohort of patients with Eisenmenger syndrome"
    explanation: Names the three associated domains curated in this node.
  - reference: PMID:32174228
    reference_title: "Determinants of Sudden Cardiac Death in Adult Patients With Eisenmenger Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical heart failure symptoms (New York Heart Association class ≥II) were predictive of increased mortality but not of SCD, suggesting a potential arrhythmic cause behind SCD."
    explanation: Supports separating the arrhythmic route to sudden death from the heart-failure route to overall mortality; the inference is the authors' own and is stated as a suggestion, hence PARTIAL.
  downstream:
  - target: Sudden cardiac death
    causal_link_type: DIRECT
    description: >
      Atrial fibrillation and conduction system disease are the arrhythmic substrate
      through which this disease produces sudden death, as distinct from the progressive
      pump failure that produces the rest of its mortality.
    evidence:
    - reference: PMID:32174228
      reference_title: "Determinants of Sudden Cardiac Death in Adult Patients With Eisenmenger Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Atrial arrhythmias, impaired ventricular function, and conduction system disease were associated with increased risk of SCD in this cohort of patients with Eisenmenger syndrome, providing an opportunity for early risk stratification and potential intervention."
      explanation: Directly links the arrhythmic and conduction-system substrate to sudden cardiac death risk in this disease.
- name: Chronic hypoxaemia and secondary erythrocytosis
  description: >
    Sustained arterial desaturation drives renal erythropoietin release and an appropriate
    compensatory rise in red cell mass. The rise is adaptive, not pathological in itself,
    and the historical practice of routine venesection to lower it is now recognised as
    harmful because it induces iron deficiency. Iron-deficient erythrocytes are less
    deformable, and iron deficiency, not haematocrit, is what tracks with symptoms and
    stroke risk.
  biological_scale: ORGANISM
  downstream:
  - target: Hyperviscosity and haemostatic derangement
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >
      Raised red cell mass increases whole-blood viscosity, though the correlation with
      symptoms is weaker than historically assumed.
    evidence:
    - reference: PMID:39711759
      reference_title: "Update on Eisenmenger syndrome - Review of pathophysiology and recent progress in risk assessment and management."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "While this does occur in the context of cyanosis and secondary erythrocytosis, there is a tenuous correlation between hematocrit and viscosity, iron deficiency, or a patient's severity or frequency of symptoms"
      explanation: Confirms hyperviscosity occurs on the background of secondary erythrocytosis while explicitly weakening the quantitative link, which is why the edge is curated PARTIAL and as indirect.
  evidence:
  - reference: PMID:39711759
    reference_title: "Update on Eisenmenger syndrome - Review of pathophysiology and recent progress in risk assessment and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "While this does occur in the context of cyanosis and secondary erythrocytosis, there is a tenuous correlation between hematocrit and viscosity, iron deficiency, or a patient's severity or frequency of symptoms"
    explanation: Records the weak link between haematocrit and symptoms, which is the evidence base for abandoning haematocrit-triggered venesection.
  - reference: PMID:9556469
    reference_title: "The Eisenmenger syndrome in adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Erythrocytosis is present in most patients, but excessive phlebotomy may cause microcytosis and exacerbate the symptoms of hyperviscosity."
    explanation: States both that erythrocytosis is near-universal and that over-treating it with phlebotomy is counterproductive.
- name: Hyperviscosity and haemostatic derangement
  description: >
    The haematologic consequence is bidirectional and awkward to manage: patients carry
    both a thrombotic tendency (in situ pulmonary artery thrombosis, paradoxical embolism)
    and a bleeding diathesis (haemoptysis, mucosal bleeding, perioperative haemorrhage).
    Pulmonary artery thrombosis in this disease tracks with biventricular dysfunction and
    slow pulmonary flow rather than with haematocrit or clotting-factor abnormalities,
    which argues for stasis rather than hypercoagulability as its proximate cause.
  biological_scale: ORGANISM
  downstream:
  - target: Multisystem complications of chronic cyanosis
    causal_link_type: DIRECT
    description: >
      The combined thrombotic and haemorrhagic tendency contributes to stroke, haemoptysis,
      and bleeding complications.
    evidence:
    - reference: PMID:9556469
      reference_title: "The Eisenmenger syndrome in adults."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The hemostatic changes associated with the syndrome may lead to thromboembolic events, cerebrovascular complications, or the hyperviscosity syndrome."
      explanation: Links the haemostatic derangement directly to thromboembolic and cerebrovascular complications.
  evidence:
  - reference: PMID:9556469
    reference_title: "The Eisenmenger syndrome in adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The hemostatic changes associated with the syndrome may lead to thromboembolic events, cerebrovascular complications, or the hyperviscosity syndrome."
    explanation: Establishes the haemostatic derangement and its thromboembolic and cerebrovascular consequences.
  - reference: PMID:17692749
    reference_title: "Pulmonary arterial thrombosis in eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These patients were older (p = 0.032), but did not differ in oxygen saturation, hemoglobin, or hematocrit from those without thrombus."
    explanation: Argues against erythrocytosis as the driver of pulmonary artery thrombosis, since thrombus-positive and thrombus-negative patients had indistinguishable haemoglobin and haematocrit.
  - reference: PMID:17692749
    reference_title: "Pulmonary arterial thrombosis in eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Those with thrombus also had a larger main pulmonary artery diameter (48 +/- 14 mm vs. 38 +/- 9 mm, p = 0.007) and a lower peak systolic velocity in the pulmonary artery (p = 0.003)."
    explanation: Identifies a dilated main pulmonary artery and slow pulmonary arterial flow, rather than a clotting abnormality, as the correlates of thrombus.
- name: Loss of pulmonary filtration of venous emboli
  description: >
    With a right-to-left shunt the pulmonary capillary bed no longer filters the venous
    return, so thrombi and septic emboli pass directly into the systemic arterial
    circulation. This is the mechanism behind paradoxical embolic stroke and behind
    cerebral abscess, and it is why meticulous air-filtering of intravenous lines and
    endocarditis prophylaxis matter more here than in an acyanotic patient.
  biological_scale: ORGANISM
  downstream:
  - target: Multisystem complications of chronic cyanosis
    causal_link_type: DIRECT
    description: >
      Unfiltered emboli reaching the systemic circulation produce stroke and brain abscess.
    evidence:
    - reference: PMID:35331414
      reference_title: "Eisenmenger Syndrome: JACC State-of-the-Art Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "increased thrombotic and bleeding diathesis"
      explanation: Supports the thrombotic diathesis feeding the systemic complication burden; the abstract does not itself name paradoxical embolism, hence PARTIAL.
  evidence:
  - reference: PMID:9556469
    reference_title: "The Eisenmenger syndrome in adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The hemostatic changes associated with the syndrome may lead to thromboembolic events, cerebrovascular complications, or the hyperviscosity syndrome."
    explanation: Documents the cerebrovascular consequence; the review attributes it to haemostatic change, so the loss-of-filtration route specifically is curated as PARTIAL rather than SUPPORT.
- name: Multisystem complications of chronic cyanosis
  description: >
    Beyond the heart and lungs, sustained cyanosis and high red cell turnover produce a
    recognisable multiorgan burden: hyperuricaemia and gout, pigment cholelithiasis from
    chronic hyperbilirubinaemia, renal impairment with proteinuria, hypertrophic
    osteoarthropathy, and neurologic events. These are what make Eisenmenger syndrome a
    systemic disease rather than a cardiopulmonary one.
  biological_scale: ORGANISM
  evidence:
  - reference: PMID:9556469
    reference_title: "The Eisenmenger syndrome in adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other complications associated with the Eisenmenger syndrome include hemoptysis, gout, cholelithiasis, hypertrophic osteoarthropathy, and decreased renal function."
    explanation: Enumerates the multisystem complication set curated in this node.
  - reference: PMID:35331414
    reference_title: "Eisenmenger Syndrome: JACC State-of-the-Art Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "remains a complex clinical entity with multisystem involvement, including secondary erythrocytosis, increased thrombotic and bleeding diathesis, high arrhythmogenic risk, progressive heart failure, and premature death"
    explanation: State-of-the-art review characterising the disease as multisystem, with the specific domains listed.
phenotypes:
- category: Functional
  name: Central cyanosis
  description: >
    Arterial desaturation from right-to-left shunting, the cardinal clinical
    manifestation and the sign that gives the syndrome its clinical identity.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Central cyanosis
    term:
      id: HP:0034032
      label: Central cyanosis
  evidence:
  - reference: PMID:32690623
    reference_title: "Eisenmenger syndrome: diagnosis, prognosis and clinical management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Central cyanosis is the primary clinical manifestation leading to secondary erythrocytosis and various multiorgan complications that increase morbidity and affect quality of life."
    explanation: Names central cyanosis the primary clinical manifestation, supporting a near-universal frequency band.
- category: Cardiovascular
  name: Pulmonary arterial hypertension
  description: >
    Sustained elevation of pulmonary arterial pressure from obstructive pulmonary vascular
    remodeling. Present by definition.
  frequency: OBLIGATE
  phenotype_term:
    preferred_term: Pulmonary arterial hypertension
    term:
      id: HP:0002092
      label: Pulmonary arterial hypertension
  evidence:
  - reference: PMID:39711759
    reference_title: "Update on Eisenmenger syndrome - Review of pathophysiology and recent progress in risk assessment and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Eisenmenger syndrome (ES) is defined as pulmonary hypertension due to a high pulmonary vascular resistance with reversed or bidirectional shunt"
    explanation: Pulmonary hypertension is part of the operational definition, hence OBLIGATE.
- category: Hematologic
  name: Secondary erythrocytosis
  description: >
    Hypoxia-driven erythropoietin release raises red cell mass. Compensatory rather than
    pathological, and present in most patients.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Increased hematocrit
    term:
      id: HP:0001899
      label: Increased hematocrit
  evidence:
  - reference: PMID:9556469
    reference_title: "The Eisenmenger syndrome in adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Erythrocytosis is present in most patients"
    explanation: Directly supports a very frequent band.
- category: Functional
  name: Exertional dyspnoea
  description: >
    Breathlessness on exertion, typically the presenting symptom, reflecting both fixed
    pulmonary vascular obstruction and exertional worsening of right-to-left shunting.
  phenotype_term:
    preferred_term: Exertional dyspnea
    term:
      id: HP:0002875
      label: Exertional dyspnea
  evidence:
  - reference: PMID:24012036
    reference_title: "Effects of inhaled iloprost on exercise capacity, quality of life, and cardiac function in patients with pulmonary arterial hypertension secondary to congenital heart disease (the Eisenmenger syndrome) (from the EIGER Study)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Eighteen consecutive patients with ES and exertional dyspnea according to the World Health Organization functional class III or IV were prospectively recruited."
    explanation: Exertional dyspnoea used as the defining clinical entry criterion for an Eisenmenger trial cohort.
- category: Functional
  name: Exercise intolerance
  description: >
    Objectively reduced exercise capacity, more impaired in Eisenmenger syndrome than in
    other complex cyanotic congenital heart disease, and improvable with pulmonary
    vasodilator therapy.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Exercise intolerance
    term:
      id: HP:0003546
      label: Exercise intolerance
  evidence:
  - reference: PMID:20439122
    reference_title: "Exercise performance and quality of life is more impaired in Eisenmenger syndrome than in complex cyanotic congenital heart disease with pulmonary stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Exercise performance and quality of life is more impaired in Eisenmenger syndrome than in complex cyanotic congenital heart disease with pulmonary stenosis"
    explanation: Comparative study establishing that exercise impairment in this disease exceeds that of other cyanotic congenital heart disease.
- category: Physical
  name: Digital clubbing
  description: >
    Clubbing of the fingers and toes from chronic hypoxaemia. In patent-ductus-associated
    disease it is classically differential, sparing the upper limbs, because the reversed
    ductal flow enters the aorta distal to the head and arm vessels.
  phenotype_term:
    preferred_term: Clubbing
    term:
      id: HP:0001217
      label: Clubbing
  evidence:
  - reference: PMID:35331414
    reference_title: "Eisenmenger Syndrome: JACC State-of-the-Art Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "remains a complex clinical entity with multisystem involvement, including secondary erythrocytosis, increased thrombotic and bleeding diathesis, high arrhythmogenic risk, progressive heart failure, and premature death"
    explanation: The state-of-the-art review characterises the multisystem cyanotic phenotype of which clubbing forms part; the abstract does not name clubbing itself, so this is curated as PARTIAL.
- category: Hematologic
  name: Iron deficiency
  description: >
    Common and clinically important, both because it is induced by inappropriate
    venesection and because it independently reduces exercise capacity and quality of
    life. Replacement is safe and effective, and correcting it does not require lowering
    the red cell mass.
  phenotype_term:
    preferred_term: Iron deficiency anemia
    term:
      id: HP:0001891
      label: Iron deficiency anemia
  evidence:
  - reference: PMID:20580108
    reference_title: "Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Iron deficiency is common in cyanotic congenital heart disease (CHD) and results in reduced exercise tolerance."
    explanation: Establishes iron deficiency as common in this population and functionally consequential.
- category: Respiratory
  name: Haemoptysis
  description: >
    Bleeding from dilated bronchial collaterals, ruptured pulmonary vessels, or pulmonary
    infarction. Historically the third commonest cause of death, now displaced to fifth in
    the modern therapy era.
  phenotype_term:
    preferred_term: Hemoptysis
    term:
      id: HP:0002105
      label: Hemoptysis
  evidence:
  - reference: PMID:9556469
    reference_title: "The Eisenmenger syndrome in adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other complications associated with the Eisenmenger syndrome include hemoptysis, gout, cholelithiasis, hypertrophic osteoarthropathy, and decreased renal function."
    explanation: Lists haemoptysis among the recognised complications.
  - reference: PMID:39711759
    reference_title: "Update on Eisenmenger syndrome - Review of pathophysiology and recent progress in risk assessment and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hemoptysis has decreased significantly as the cause of death, from 3rd most common to 5th most common"
    explanation: Quantifies the shift in haemoptysis as a terminal event between the pre- and post-drug-therapy eras.
- category: Neurologic
  name: Stroke
  description: >
    Ischaemic or haemorrhagic, arising from paradoxical embolism across the reversed
    shunt, in situ thrombosis, or the bleeding diathesis.
  phenotype_term:
    preferred_term: Stroke
    term:
      id: HP:0001297
      label: Stroke
  evidence:
  - reference: PMID:9556469
    reference_title: "The Eisenmenger syndrome in adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The hemostatic changes associated with the syndrome may lead to thromboembolic events, cerebrovascular complications, or the hyperviscosity syndrome."
    explanation: Documents cerebrovascular complications as a recognised consequence.
- category: Rheumatologic
  name: Gout
  description: >
    Hyperuricaemia from increased red cell turnover and reduced renal urate clearance
    precipitates gouty arthritis.
  phenotype_term:
    preferred_term: Gout
    term:
      id: HP:0001997
      label: Gout
  evidence:
  - reference: PMID:9556469
    reference_title: "The Eisenmenger syndrome in adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other complications associated with the Eisenmenger syndrome include hemoptysis, gout, cholelithiasis, hypertrophic osteoarthropathy, and decreased renal function."
    explanation: Lists gout among the recognised complications.
- category: Gastrointestinal
  name: Cholelithiasis
  description: >
    Pigment gallstones from chronic haemolysis and hyperbilirubinaemia accompanying the
    expanded red cell mass.
  phenotype_term:
    preferred_term: Cholelithiasis
    term:
      id: HP:0001081
      label: Cholelithiasis
  evidence:
  - reference: PMID:9556469
    reference_title: "The Eisenmenger syndrome in adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other complications associated with the Eisenmenger syndrome include hemoptysis, gout, cholelithiasis, hypertrophic osteoarthropathy, and decreased renal function."
    explanation: Lists cholelithiasis among the recognised complications.
- category: Renal
  name: Renal impairment
  description: >
    Reduced glomerular filtration with proteinuria and albuminuria, reported in a large
    minority to a majority of cyanotic patients and carrying prognostic weight.
  phenotype_term:
    preferred_term: Proteinuria
    term:
      id: HP:0000093
      label: Proteinuria
  evidence:
  - reference: PMID:39711759
    reference_title: "Update on Eisenmenger syndrome - Review of pathophysiology and recent progress in risk assessment and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Albuminuria is also highly prevalent with ES and other cyanotic CHD, with a prevalence upwards of 60 %"
    explanation: Quantifies albuminuria prevalence above 60% in this population.
  - reference: PMID:9556469
    reference_title: "The Eisenmenger syndrome in adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hemoptysis, gout, cholelithiasis, hypertrophic osteoarthropathy, and decreased renal function"
    explanation: Independent listing of decreased renal function among the syndrome's complications.
- category: Cardiovascular
  name: Right ventricular failure
  description: >
    Progressive failure of the pressure-loaded right ventricle, the leading cause of death
    in both the pre- and post-drug-therapy eras.
  phenotype_term:
    preferred_term: Right ventricular failure
    term:
      id: HP:0001708
      label: Right ventricular failure
  evidence:
  - reference: PMID:39711759
    reference_title: "Update on Eisenmenger syndrome - Review of pathophysiology and recent progress in risk assessment and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "in contemporary series, the most common cause of mortality remains right heart failure, unchanged from the pre-DTT era"
    explanation: Establishes right heart failure as the leading terminal event.
- category: Electrophysiological
  name: Atrial fibrillation
  description: >
    Atrial fibrillation on a substrate of chronic right atrial stretch. It is the single
    strongest independent predictor of sudden cardiac death in this disease, carrying an
    11.45-fold increased risk in multivariate analysis, which makes it the proximate cause
    behind much of the sudden mortality rather than an incidental comorbidity.
  phenotype_term:
    preferred_term: Atrial fibrillation
    term:
      id: HP:0005110
      label: Atrial fibrillation
  evidence:
  - reference: PMID:32174228
    reference_title: "Determinants of Sudden Cardiac Death in Adult Patients With Eisenmenger Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Atrial fibrillation (11.45-fold increased risk; P<0.001) and QRS duration ≥120 ms (2.06-fold increased risk; P=0.034) remained significant predictors of SCD in the multivariate analysis"
    explanation: Quantifies the sudden-death risk conferred by atrial fibrillation in 246 patients.
- category: Functional
  name: Syncope
  description: >
    Transient loss of consciousness, documented in about 8% of a large two-centre cohort.
    Worth a caution for anyone consulting risk-stratification summaries: syncope is widely
    cited as a poor-prognosis marker in Eisenmenger syndrome, but in the largest dedicated
    sudden-death analysis prior syncope showed no significant association with sudden
    cardiac death, cardiac mortality, or all-cause mortality. It is curated here as a
    documented manifestation, not as a validated predictor.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Syncope
    term:
      id: HP:0001279
      label: Syncope
  evidence:
  - reference: PMID:32174228
    reference_title: "Determinants of Sudden Cardiac Death in Adult Patients With Eisenmenger Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A history of syncope was documented in 20 (8.1%) patients."
    explanation: Quantifies syncope at 8.1% of a 246-patient cohort, supporting an OCCASIONAL band.
  - reference: PMID:32174228
    reference_title: "Determinants of Sudden Cardiac Death in Adult Patients With Eisenmenger Syndrome."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "there was no significant association between the rare presence of coronary artery stenosis (including one case of extrinsic compression of the left main coronary artery requiring stenting), prior syncope, thromboembolism, cerebrovascular accident, phlebotomy or hemoptysis and SCD, cardiac mortality, or all-cause mortality"
    explanation: Argues against the common claim that syncope is a validated prognostic predictor in this disease, which is why the description states the caveat explicitly.
- category: Functional
  name: Fatigue
  description: >
    Non-specific tiredness and reduced stamina, reflecting the combination of arterial
    hypoxaemia, limited cardiac output, and deconditioning. No frequency is asserted: the
    only quotable source names "clinical heart failure symptoms" among the recognised
    sequelae without naming fatigue or quantifying it, so the widely repeated claim that
    fatigue is near-universal in this disease is not curated here.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
  evidence:
  - reference: PMID:32174228
    reference_title: "Determinants of Sudden Cardiac Death in Adult Patients With Eisenmenger Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical heart failure symptoms, increased risk of arrhythmias, syncope, sudden death, as well as complex hematologic, thrombotic, hemorrhagic, pulmonary, and infectious complications are all recognized sequelae of Eisenmenger syndrome."
    explanation: Places clinical heart failure symptoms, of which fatigue is the cardinal one, among the recognised sequelae; the source does not name fatigue itself, hence PARTIAL.
- category: Electrophysiological
  name: Sudden cardiac death
  description: >
    Arrhythmic death, the second or third commonest mode of death, occurring against a
    background of high arrhythmogenic risk.
  phenotype_term:
    preferred_term: Sudden cardiac death
    term:
      id: HP:0001645
      label: Sudden cardiac death
  evidence:
  - reference: PMID:35331414
    reference_title: "Eisenmenger Syndrome: JACC State-of-the-Art Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "high arrhythmogenic risk, progressive heart failure, and premature death"
    explanation: Establishes high arrhythmogenic risk and premature death; the abstract does not separately quantify sudden death, so this is PARTIAL.
  - reference: PMID:32690623
    reference_title: "Eisenmenger syndrome: diagnosis, prognosis and clinical management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Progressive heart failure, infectious diseases and sudden cardiac death comprise the main causes of death in patients with ES."
    explanation: Names sudden cardiac death among the three main causes of death.
progression:
- phase: Latent left-to-right shunt phase
  notes: >
    An initially asymptomatic or minimally symptomatic period during which the shunt is
    left-to-right and pulmonary vascular resistance is normal or only mildly elevated.
    Repair during this window prevents the syndrome entirely, and the practical target is
    intervention within the first year or two of life. Post-tricuspid lesions may traverse
    this phase within infancy; pre-tricuspid atrial defects may take three or four decades.
  evidence:
  - reference: PMID:27325590
    reference_title: "Eisenmenger syndrome and long-term survival in patients with Down syndrome and congenital heart disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The likelihood of being treated interventionally or surgically before the age of 1 year increased significantly over time. In parallel, the likelihood of developing ES decreased over time (53% birth cohort during 1950s/1960s vs 0.5% birth cohort during 2000-2009, p<0.0001)."
    explanation: Demonstrates that operating within the first year of life during the latent phase reduces progression from 53% to 0.5%.
- phase: Established Eisenmenger physiology
  notes: >
    Once pulmonary vascular resistance is fixed and the shunt has reversed, the disease is
    chronic and progressive, punctuated by complications rather than following a smooth
    decline. Defect closure is now contraindicated. Survival is substantially reduced:
    10-year survival is 57% overall and 34% among patients never given pulmonary
    vasodilator therapy, and the leading terminal event is right heart failure.
  evidence:
  - reference: PMID:39711759
    reference_title: "Update on Eisenmenger syndrome - Review of pathophysiology and recent progress in risk assessment and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Once these biases were accounted for, 10-year survival for contemporary patients with ES was 57 % in the overall cohort and 34 % in patients naïve to disease targeting therapy (DTT)"
    explanation: Gives the contemporary 10-year survival figures, corrected for the survivorship bias that inflated earlier estimates.
  - reference: PMID:25099652
    reference_title: "Survival prospects of treatment naïve patients with Eisenmenger: a systematic review of the literature and report of own experience."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "After accounting for this effect we found high standardised mortality ratios, a 10-year mortality rate approaching 30-40% and no evidence of superior survival prospects of current era patients compared with those seen in the 1970s, 1980s and 1990s."
    explanation: Systematic review of 1131 patients correcting for immortal time bias, and finding no survival improvement in treatment-naive patients across four decades.
diagnosis:
- name: Transthoracic echocardiography
  description: >
    The mainstay non-invasive test. It identifies the underlying defect, demonstrates the
    direction of shunting on colour Doppler (right-to-left or bidirectional), estimates
    pulmonary artery pressure, and assesses right ventricular size and function. A
    diagnostic pitfall worth knowing: the murmur may be quiet or absent, because equalised
    ventricular pressures abolish the turbulent gradient across the defect.
  diagnosis_term:
    preferred_term: echocardiography
    term:
      id: NCIT:C16525
      label: Echocardiography Test
  evidence:
  - reference: PMID:27002414
    reference_title: "BMPR2 mutation is a potential predisposing genetic risk factor for congenital heart disease associated pulmonary vascular disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PAH was diagnosed by heart catheterization at rest after CHD was first recognized by echocardiography."
    explanation: Documents the standard diagnostic sequence, in which echocardiography identifies the congenital defect and catheterisation then confirms the pulmonary hypertension.
- name: Right heart catheterisation
  description: >
    The confirmatory gold standard, giving direct measurement of pulmonary artery pressure,
    pulmonary vascular resistance, and oximetry at each chamber, and where relevant
    vasoreactivity testing to judge whether any operability remains. It is the test that
    distinguishes still-correctable pulmonary arterial hypertension associated with
    congenital heart disease from established, inoperable Eisenmenger physiology.
  diagnosis_term:
    preferred_term: right heart catheterization
    term:
      id: NCIT:C80411
      label: Right Heart Catheterization
  evidence:
  - reference: PMID:27002414
    reference_title: "BMPR2 mutation is a potential predisposing genetic risk factor for congenital heart disease associated pulmonary vascular disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PVD was defined as a pulmonary vascular resistance (PVR) more than 3 Wood units."
    explanation: Shows catheter-measured pulmonary vascular resistance being used as the defining diagnostic criterion for pulmonary vascular disease in congenital heart disease.
  - reference: PMID:16801459
    reference_title: "Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hemodynamics were assessed by right- and left-heart catheterization."
    explanation: Catheterisation used as the reference haemodynamic assessment in the pivotal Eisenmenger trial.
- name: Pulse oximetry
  description: >
    Resting and exertional oxygen saturation quantifies the right-to-left shunt burden and
    is itself prognostic. Because pulmonary vasodilators could in principle worsen shunting
    by dropping systemic resistance, saturation is also the key safety measurement when
    starting these drugs.
  diagnosis_term:
    preferred_term: pulse oximetry
    term:
      id: NCIT:C38085
      label: Pulse Oximetry
  evidence:
  - reference: PMID:16801459
    reference_title: "Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The placebo-corrected effect on systemic pulse oximetry was 1.0% (95% confidence interval, -0.7 to 2.8), demonstrating that bosentan did not worsen oxygen saturation."
    explanation: Pulse oximetry used as the primary safety endpoint, testing the theoretical concern that a vasodilator might worsen right-to-left shunting.
- name: Iron studies and full blood count
  description: >
    Haemoglobin, haematocrit, ferritin, and transferrin saturation characterise the
    secondary erythrocytosis and, more importantly, detect the iron deficiency that is
    treatable and functionally consequential. Interpreting haemoglobin without iron indices
    is what historically led to inappropriate venesection.
  diagnosis_term:
    preferred_term: blood cell count
    term:
      id: NCIT:C28133
      label: Blood Cell Count
  evidence:
  - reference: PMID:20580108
    reference_title: "Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "After 3 months of treatment, hemoglobin (19.0 ± 2.9 g/dL to 20.4 ± 2.7 g/dL, p<0.001), ferritin (13.3 ± 4.7 μg/L to 54.1 ± 24.2 μg/L, p<0.001) and transferrin saturation (17.8 ± 9.6% to 34.8 ± 23.4%, p<0.001) significantly increased."
    explanation: Shows ferritin and transferrin saturation being used to identify and track the iron deficiency that a haemoglobin measurement alone would conceal.
treatments:
- name: Endothelin receptor antagonist therapy
  description: >
    Bosentan is the first-line pulmonary vasodilator and the only agent tested against
    placebo in a dedicated Eisenmenger randomised trial. BREATHE-5 showed it lowered
    pulmonary vascular resistance and mean pulmonary artery pressure and increased walk
    distance without worsening systemic oxygen saturation, which had been the theoretical
    safety concern, and the open-label extension showed the gain was sustained to 40 weeks.
  context: Symptomatic Eisenmenger syndrome, typically WHO functional class III
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: bosentan
      term:
        id: CHEBI:51450
        label: bosentan
  target_phenotypes:
  - preferred_term: Pulmonary arterial hypertension
    term:
      id: HP:0002092
      label: Pulmonary arterial hypertension
  - preferred_term: Exercise intolerance
    term:
      id: HP:0003546
      label: Exercise intolerance
  target_mechanisms:
  - target: Increased pulmonary vascular resistance
    treatment_effect: INHIBITS
    description: >
      Blocking endothelin receptors relieves the endothelin-driven component of
      vasoconstriction and proliferation, lowering pulmonary vascular resistance.
    evidence:
    - reference: PMID:16801459
      reference_title: "Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Compared with placebo, bosentan reduced pulmonary vascular resistance index (-472.0 dyne.s.cm(-5); P=0.0383). The mean pulmonary arterial pressure decreased (-5.5 mm Hg; P=0.0363), and the exercise capacity increased (53.1 m; P=0.0079)."
      explanation: Placebo-controlled demonstration that endothelin blockade lowers pulmonary vascular resistance in this disease.
  evidence:
  - reference: PMID:16801459
    reference_title: "Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this first placebo-controlled trial in patients with Eisenmenger syndrome, bosentan was well tolerated and improved exercise capacity and hemodynamics without compromising peripheral oxygen saturation."
    explanation: The pivotal randomised trial conclusion, addressing both efficacy and the shunt-worsening safety concern.
  - reference: PMID:17658633
    reference_title: "Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At week 24, the 6-minute walk distance (mean+/-SE) increased from OLE baseline for the ex-placebo (+33.2+/-23.9 m) and ex-bosentan group (+6.7+/-10.0 m)."
    explanation: Open-label extension showing the walk-distance gain is maintained and extended out to 40 weeks of exposure.
  - reference: PMID:27054605
    reference_title: "Advanced Therapy in Eisenmenger Syndrome: A Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Advanced therapy with pulmonary vasodilators has become part of the standard treatment, offering long-term benefits on exercise capacity, clinical symptoms, and possibly survival."
    explanation: Systematic review establishing pulmonary vasodilators as standard treatment, while hedging the survival claim as only possible, which is why survival benefit is not asserted here.
  - reference: PMID:27054605
    reference_title: "Advanced Therapy in Eisenmenger Syndrome: A Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, there are currently only few studies to guide the use of advanced therapies in this population, and important questions such as indications for initiation or escalation of advanced therapy and valid effect parameters and treatment goals remain unanswered."
    explanation: Records that the evidence base does not settle when to start or escalate these drugs, which is the honest limit on how prescriptive this entry can be.
- name: Phosphodiesterase-5 inhibitor therapy
  description: >
    Sildenafil and tadalafil potentiate nitric-oxide-mediated pulmonary vasodilation, the
    arm of endothelial function that is depressed in this disease. Used as add-on to an
    endothelin antagonist or, in some settings, as monotherapy. Added to bosentan,
    sildenafil did not further improve walk distance but did raise resting oxygen
    saturation, an honest split result worth recording.
  context: Symptomatic disease, as add-on to an endothelin receptor antagonist or as monotherapy
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: sildenafil
      term:
        id: CHEBI:9139
        label: sildenafil
  target_phenotypes:
  - preferred_term: Pulmonary arterial hypertension
    term:
      id: HP:0002092
      label: Pulmonary arterial hypertension
  target_mechanisms:
  - target: Shear-stress-mediated pulmonary endothelial dysfunction
    treatment_effect: RESTORES
    description: >
      Inhibiting phosphodiesterase-5 preserves cyclic GMP downstream of nitric oxide,
      compensating pharmacologically for the depressed endothelial nitric oxide arm.
    evidence:
    - reference: PMID:20202971
      reference_title: "Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Adding sildenafil to bosentan did not improve the 6 MWD significantly (21 vs. 8 m, P = 0.48), but increased saturation at rest (2.9 vs. -1.8%, P < 0.01)."
      explanation: The saturation gain is consistent with improved pulmonary vasodilation, but the absence of a walk-distance effect means the mechanism claim is supported only partially.
  evidence:
  - reference: PMID:20202971
    reference_title: "Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In Eisenmenger syndrome, treatment with bosentan significantly improved walking distance, pulmonary blood flow, and PVR. Adding sildenafil to bosentan did not significantly improve walking distance but did increase saturation at rest."
    explanation: Randomised cross-over trial in 21 patients giving a mixed result for add-on sildenafil, which is why the entry does not claim unqualified benefit.
  - reference: PMID:20304507
    reference_title: "Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy"
    explanation: Independent report of functional and quality-of-life benefit from sildenafil in this population.
- name: Prostanoid therapy
  description: >
    Inhaled iloprost and parenteral prostacyclin analogues replace the deficient
    prostacyclin arm of endothelial signalling. In the EIGER study inhaled iloprost improved
    walk distance, quality of life, and right ventricular performance, notably without
    changing pulmonary artery pressure or resistance, which suggests the functional gain
    is not purely haemodynamic.
  context: Symptomatic disease, often in functional class III-IV or after inadequate response to oral agents
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: iloprost
      term:
        id: CHEBI:63916
        label: iloprost
  target_phenotypes:
  - preferred_term: Exercise intolerance
    term:
      id: HP:0003546
      label: Exercise intolerance
  notes: >
    The dissociation between improved symptoms and unchanged pulmonary haemodynamics is
    recorded deliberately: it means walk distance and quality of life in this disease are
    not simple read-outs of pulmonary vascular resistance, and a drug can help without
    measurably remodelling the pulmonary bed.
  evidence:
  - reference: PMID:24012036
    reference_title: "Effects of inhaled iloprost on exercise capacity, quality of life, and cardiac function in patients with pulmonary arterial hypertension secondary to congenital heart disease (the Eisenmenger syndrome) (from the EIGER Study)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "After 24 weeks of iloprost therapy, 6-minute walk test distance significantly increased (289.1 ± 76.9 to 369.5 ± 93.4 m, p = 0.032)"
    explanation: Prospective study showing a substantial walk-distance gain with inhaled iloprost.
  - reference: PMID:24012036
    reference_title: "Effects of inhaled iloprost on exercise capacity, quality of life, and cardiac function in patients with pulmonary arterial hypertension secondary to congenital heart disease (the Eisenmenger syndrome) (from the EIGER Study)."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Pulmonary arterial pressure and pulmonary vascular resistance did not improve with iloprost therapy."
    explanation: Argues against a haemodynamic mechanism for the observed functional benefit, and is curated so the treatment is not presented as resistance-lowering.
- name: Iron replacement therapy
  description: >
    Oral or intravenous iron corrects the iron deficiency that is common in cyanotic
    congenital heart disease, improving exercise capacity and quality of life. It is the
    modern replacement for the discredited practice of routine venesection, and it raises
    rather than lowers haemoglobin.
  context: Documented iron deficiency, identified on ferritin and transferrin saturation rather than haemoglobin alone
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: iron(2+)
      term:
        id: CHEBI:29033
        label: iron(2+)
  target_phenotypes:
  - preferred_term: Iron deficiency anemia
    term:
      id: HP:0001891
      label: Iron deficiency anemia
  - preferred_term: Exercise intolerance
    term:
      id: HP:0003546
      label: Exercise intolerance
  notes: >
    The counterpart caution belongs with it: routine phlebotomy to lower haematocrit is
    not indicated and is actively harmful, because it induces the very iron deficiency
    this treatment corrects.
  evidence:
  - reference: PMID:20580108
    reference_title: "Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Significant improvements were also detected in the total CAMPHOR score (20.7 ± 10.9 to 16.2 ± 10.4, p=0.001) and 6MWT distance (371.7 ± 84.7 m to 402.8.0±74.9m, p=0.001)."
    explanation: Prospective study showing quality-of-life and walk-distance gains from iron replacement.
  - reference: PMID:9556469
    reference_title: "The Eisenmenger syndrome in adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Erythrocytosis is present in most patients, but excessive phlebotomy may cause microcytosis and exacerbate the symptoms of hyperviscosity."
    explanation: Supports the accompanying caution against venesection, which causes the microcytosis that iron replacement is given to reverse.
- name: Heart-lung or bilateral lung transplantation
  description: >
    The only intervention that alters the underlying disease rather than its symptoms.
    Strategy depends on the defect: for atrial septal defects, bilateral lung
    transplantation with concurrent defect repair gives outcomes at least as good as
    combined heart-lung transplantation, whereas ventricular septal defect disease has
    historically favoured heart-lung. Perioperative bleeding risk is elevated by the
    haemostatic derangement.
  context: Advanced disease refractory to pulmonary vasodilator therapy
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: NCIT:C15289
      label: Organ Transplantation
  target_phenotypes:
  - preferred_term: Right ventricular failure
    term:
      id: HP:0001708
      label: Right ventricular failure
  evidence:
  - reference: PMID:34112578
    reference_title: "Waitlist and post-transplant outcomes for eisenmenger syndrome: A comparison of transplant strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LTx shows superior survival outcomes in the current era for ES ASD patients, and equivalent outcomes for ES-VSD."
    explanation: ISHLT and OPTN registry analysis establishing that the optimal transplant strategy differs by underlying defect.
  - reference: PMID:34112578
    reference_title: "Waitlist and post-transplant outcomes for eisenmenger syndrome: A comparison of transplant strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Compared to LTx for other indications, the odds of transplantation were significantly less for both ES-ASD"
    explanation: Records that Eisenmenger patients are markedly less likely to actually reach transplantation than other lung transplant candidates, which qualifies how available this option is in practice.
  - reference: PMID:32565271
    reference_title: "Not All Septal Defects Are Equal: Outcomes of Bilateral Lung Transplant With Cardiac Defect Repair vs Combined Heart-Lung Transplant in Patients With Eisenmenger Syndrome in the United States."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "During the study period, 442 adults with ES underwent thoracic transplantation (316 HLTs and 126 BLTs). Following BLT, overall survival 1, 5, and 10 years' posttransplant was 63.1%, 38.5%, and 30.2%, respectively."
    explanation: United Network for Organ Sharing analysis of 442 Eisenmenger transplants giving absolute survival figures for the bilateral lung strategy, and independently addressing which strategy suits which defect.
  - reference: PMID:32565271
    reference_title: "Not All Septal Defects Are Equal: Outcomes of Bilateral Lung Transplant With Cardiac Defect Repair vs Combined Heart-Lung Transplant in Patients With Eisenmenger Syndrome in the United States."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thoracic transplantation is considered for patients with Eisenmenger syndrome (ES) who have refractory right ventricular failure despite optimal therapy for pulmonary arterial hypertension."
    explanation: States the indication curated in this treatment's context field, namely refractory right ventricular failure despite optimal pulmonary vasodilator therapy.
genetic:
- name: BMPR2
  gene_term:
    preferred_term: BMPR2
    term:
      id: hgnc:1078
      label: BMPR2
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: >
    BMPR2 is the canonical heritable pulmonary arterial hypertension gene, and variants are
    enriched in congenital heart disease patients who go on to develop pulmonary vascular
    disease relative to those who do not. It is best understood as a susceptibility factor
    that lowers the haemodynamic threshold for irreversible remodeling, not as a cause of
    Eisenmenger syndrome, which requires the anatomic shunt. The enrichment is most marked
    in patients whose defect was repaired yet who still developed pulmonary vascular
    disease, exactly the group in whom haemodynamics alone fail to explain the outcome.
  case_fractions:
  - population: Chinese cohort of congenital heart disease with pulmonary vascular disease
    case_fraction_percent: 7.5
    cohort_size: 294
    notes: 22 of 294 CHD-PVD patients carried a BMPR2 mutation, versus 2 of 161 (1.2%) CHD patients without pulmonary vascular disease.
    evidence:
    - reference: PMID:27002414
      reference_title: "BMPR2 mutation is a potential predisposing genetic risk factor for congenital heart disease associated pulmonary vascular disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "A total of 24 mutations were identified, accounting for 22 of the 294 patients with CHD-PVD (7.5%) and 2 of the 161 CHD patients without PVD (1.2%, P=0.004)."
      explanation: Quantifies the BMPR2 enrichment in congenital heart disease with pulmonary vascular disease against a congenital heart disease control group.
  evidence:
  - reference: PMID:27002414
    reference_title: "BMPR2 mutation is a potential predisposing genetic risk factor for congenital heart disease associated pulmonary vascular disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genetic predisposing factor may be an important component in the process of development of PVD in CHD patients."
    explanation: The study's own conclusion, framed as predisposition rather than causation.
  - reference: PMID:27002414
    reference_title: "BMPR2 mutation is a potential predisposing genetic risk factor for congenital heart disease associated pulmonary vascular disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A significant higher BMPR2 mutation rate (12.6%) was found in repaired CHD-PVD (P=0.010). BMPR2 mutations in CHD-PVD patients were identified in different clinical phenotypes. Missense mutation of BMPR2 is the dominant mutation type."
    explanation: Shows the enrichment concentrating in repaired patients, and identifies missense as the dominant variant class.
- name: ACVRL1
  gene_term:
    preferred_term: ACVRL1
    term:
      id: hgnc:175
      label: ACVRL1
  relationship_type: UNKNOWN
  variant_origin: GERMLINE
  notes: >
    ACVRL1 (ALK1) encodes a BMP9/10 co-receptor, is an established heritable pulmonary
    arterial hypertension gene, and appears alongside BMPR2 on the clinical gene panel
    used when heritable pulmonary arterial hypertension is suspected in this setting. Its
    relationship to Eisenmenger syndrome specifically is UNKNOWN rather than
    SUSCEPTIBILITY or DISPUTED: nothing contests the gene's role in pulmonary arterial
    hypertension, but unlike BMPR2 no cohort has shown it enriched in congenital heart
    disease with pulmonary vascular disease relative to congenital heart disease without
    it. Panel membership is the only support, which is absence of Eisenmenger-specific
    evidence rather than contested evidence. No evidence item is attached, because no
    cached source makes a claim about this gene in this disease; the argument lives here
    per the evidence SOP.
- name: ENG
  gene_term:
    preferred_term: ENG
    term:
      id: hgnc:3349
      label: ENG
  relationship_type: UNKNOWN
  variant_origin: GERMLINE
  notes: >
    ENG (endoglin) encodes the other BMP9/10 co-receptor component and sits on the same
    heritable pulmonary arterial hypertension gene panel as ACVRL1 and BMPR2. It carries
    the same UNKNOWN relationship for the same reason, and for the same reason no evidence
    item is attached. It is curated as its own record rather than bundled with ACVRL1 so
    that each gene carries its own binding.
- name: Trisomy 21
  relationship_type: RISK_FACTOR
  variant_origin: GERMLINE
  notes: >
    Trisomy 21 is the principal chromosomal risk factor. Children with Down syndrome and a
    post-tricuspid shunt progress to Eisenmenger physiology at higher rates and younger
    ages than other children with comparable lesions, and historically over half of them
    did so. The risk is not fixed biology: it fell to under 1% once early surgical repair
    became routine, which makes trisomy 21 a modifier of the timeline rather than an
    independent path to the syndrome.
  evidence:
  - reference: PMID:27325590
    reference_title: "Eisenmenger syndrome and long-term survival in patients with Down syndrome and congenital heart disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the likelihood of developing ES decreased over time (53% birth cohort during 1950s/1960s vs 0.5% birth cohort during 2000-2009, p<0.0001)"
    explanation: German National Register data on 894 Down syndrome patients with post-tricuspid shunts.
  - reference: PMID:27325590
    reference_title: "Eisenmenger syndrome and long-term survival in patients with Down syndrome and congenital heart disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with ES had a significantly worse survival compared with those without ES (HR 18.1; 95% CI 7.2 to 45.4; p<0.0001)."
    explanation: Quantifies the survival cost of developing Eisenmenger syndrome within the Down syndrome congenital heart disease population.
biochemical:
- name: Brain natriuretic peptide
  presence: INCREASED
  biomarker_term:
    preferred_term: brain natriuretic peptide
    term:
      id: NCIT:C88523
      label: Brain Natriuretic Peptide 32
  notes: >
    Serum brain natriuretic peptide is an independent prognostic predictor in Eisenmenger
    syndrome, rising with right ventricular dysfunction. It is a risk marker rather than a
    diagnostic test, and no externally validated risk score incorporating it yet exists
    for this disease. Note the analyte: both cited sources say "brain natriuretic peptide"
    (BNP), so the term bound here is BNP itself and not the N-terminal fragment
    (NT-proBNP) that sibling pulmonary arterial hypertension entries curate. The two are
    different molecules measured by different assays and should not be conflated.
  evidence:
  - reference: PMID:40204597
    reference_title: "Risk stratification in Eisenmenger syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Several risk factors have been identified as independent predictors in Eisenmenger syndrome, including the 6-minute walk distance, echocardiographic markers and serum brain natriuretic peptide."
    explanation: Names serum brain natriuretic peptide among the independent prognostic predictors.
  - reference: PMID:32690623
    reference_title: "Eisenmenger syndrome: diagnosis, prognosis and clinical management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Impaired exercise tolerance, decreased arterial oxygen saturation, iron deficiency, pre-tricuspid shunts, arrhythmias, increased brain natriuretic peptide, echocardiographic indices of right ventricular dysfunction and hospitalisation for heart failure predict mortality."
    explanation: Independent listing of raised brain natriuretic peptide among the mortality predictors, alongside the arrhythmia and iron-deficiency features curated elsewhere in this entry.
clinical_trials:
- name: NCT01743001
  phase: PHASE_III
  status: COMPLETED
  description: >-
    MAESTRO. Multicentre, double-blind, randomised, placebo-controlled, parallel-group
    phase 3 trial of macitentan for exercise capacity in Eisenmenger syndrome. It is the
    largest randomised trial conducted specifically in this disease. This entry curates
    bosentan rather than macitentan as the endothelin antagonist with Eisenmenger-specific
    randomised support, because BREATHE-5 is the trial whose positive result is quotable
    from a cached abstract; no cached source in this entry reports the MAESTRO outcome, so
    none is asserted here.
  target_phenotypes:
  - preferred_term: Exercise intolerance
    term:
      id: HP:0003546
      label: Exercise intolerance
  evidence:
  - reference: clinicaltrials:NCT01743001
    reference_title: "A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome"
    supports: SUPPORT
    snippet: "Clinical study to assess the efficacy, safety, and tolerability of macitentan in subjects with Eisenmenger Syndrome."
    explanation: Registry record for the phase 3 macitentan exercise-capacity trial in Eisenmenger syndrome.
- name: NCT01739400
  phase: PHASE_III
  status: COMPLETED
  description: >-
    Long-term single-arm open-label extension of the MAESTRO protocol, assessing safety,
    tolerability and efficacy of macitentan in Eisenmenger syndrome beyond the randomised
    period.
  target_phenotypes:
  - preferred_term: Pulmonary arterial hypertension
    term:
      id: HP:0002092
      label: Pulmonary arterial hypertension
  evidence:
  - reference: clinicaltrials:NCT01739400
    reference_title: "Long Term, Single-arm, Open-label Extension Study of Protocol AC-055-305 to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome"
    supports: SUPPORT
    snippet: "Long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of Eisenmenger syndrome."
    explanation: Registry record for the open-label extension of the macitentan programme in Eisenmenger syndrome.
prevalence:
- population: Adults with congenital heart disease, contemporary registries in high-resource settings
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  notes: >
    Between 1% and 5.7% of contemporary congenital heart disease registry populations,
    down from the 17.5% Paul Wood described in 1958. The denominator here is patients with
    congenital heart disease, not the general population, so the prevalence class reflects
    frequency within that population rather than population prevalence. The decline is
    attributable to early surgical repair and is not seen in regions with limited access
    to paediatric cardiac surgery.
  evidence:
  - reference: PMID:39711759
    reference_title: "Update on Eisenmenger syndrome - Review of pathophysiology and recent progress in risk assessment and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "to between 1 and 5.7 % in more contemporary registries"
    explanation: Gives the contemporary registry range. The same sentence records the historical 17.5% figure Paul Wood described in 1958, but that clause carries an inline citation marker that the reference validator strips, so the quoted portion is the bracket-free tail.
  - reference: PMID:39711759
    reference_title: "Update on Eisenmenger syndrome - Review of pathophysiology and recent progress in risk assessment and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, a similar trend may not be seen in patients from regions with less robust access to medical resources"
    explanation: Records that the decline is confined to high-resource settings, so the contemporary figure should not be generalised globally.
- population: Down syndrome with a post-tricuspid shunt lesion, German National Register
  measure_type: PERIOD_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  notes: >
    53% of the 1950s-1960s birth cohort developed Eisenmenger syndrome, versus 0.5% of the
    2000-2009 birth cohort, in 894 patients with Down syndrome and a post-tricuspid shunt.
    The two figures are the same population separated only by access to early surgery.
  evidence:
  - reference: PMID:27325590
    reference_title: "Eisenmenger syndrome and long-term survival in patients with Down syndrome and congenital heart disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Out of 1549 patients with DS with congenital heart disease in the National Register for Congenital Heart Defects, 894 patients (55% female, mean age 17.5 years) had a post-tricuspid shunt lesion"
    explanation: Defines the register cohort from which the birth-cohort progression rates are drawn.
differential_diagnoses:
- name: Idiopathic pulmonary arterial hypertension
  description: >
    Shares the pulmonary vascular lesion but has no structural shunt. The distinction is
    not academic: without a decompressing shunt the right ventricle bears the full
    afterload, so idiopathic disease carries worse haemodynamics and shorter survival at
    equivalent pulmonary pressures, and the treatment goal is unequivocally to lower
    pulmonary vascular resistance rather than to preserve a protective shunt.
  disease_term:
    preferred_term: idiopathic pulmonary arterial hypertension
    term:
      id: MONDO:0001999
      label: idiopathic pulmonary arterial hypertension
  distinguishing_features:
  - No structural intracardiac or aortopulmonary communication
  - No right-to-left shunt, so no central cyanosis from shunting and no secondary erythrocytosis
  - Worse haemodynamics and survival at comparable pulmonary artery pressures
  - Defect closure is not a consideration; there is no shunt to preserve or close
  evidence:
  - reference: PMID:19245962
    reference_title: "Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although ES shares similar morphological findings with idiopathic PAH, clinical differences exist between the 2 etiologies. Adults with ES exhibit increased survival and more favorable hemodynamics than those with idiopathic PAH."
    explanation: States both the shared pulmonary vascular morphology and the divergent clinical course that separates the two entities.
- name: Operable pulmonary arterial hypertension associated with congenital heart disease
  description: >
    The same disease at an earlier point on its trajectory, before pulmonary vascular
    resistance becomes fixed and the shunt reverses. This is the single most consequential
    distinction in the entry, because the two are managed in opposite directions: the
    operable patient should have the defect closed, and the Eisenmenger patient must not.
    Right heart catheterisation with vasoreactivity testing is what separates them.
  distinguishing_features:
  - Shunt still predominantly left-to-right, without resting cyanosis
  - Pulmonary vascular resistance not yet fixed, and may fall on vasoreactivity testing
  - Defect closure indicated rather than contraindicated
  - Secondary erythrocytosis and the multisystem cyanotic complications are absent
  evidence:
  - reference: PMID:33853494
    reference_title: "Preventing disease progression in Eisenmenger syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Once Eisenmenger syndrome develops, shunt closure should be avoided."
    explanation: States the management divergence that makes this differential decisive.
  - reference: PMID:31120797
    reference_title: "Eisenmenger syndrome and other types of pulmonary arterial hypertension related to adult congenital heart disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PAH-CHD describes a wide spectrum of conditions, of which ES is the archetype."
    explanation: Positions Eisenmenger syndrome as the severe end of a spectrum, the earlier parts of which remain operable.
clinical_burden:
  burden_level: HIGH
  rationale: >
    A lifelong, progressive, multisystem disease with 10-year survival of 57% overall and
    34% without pulmonary vasodilator therapy, no curative option short of transplantation,
    and an absolute contraindication to pregnancy in a population that reaches childbearing
    age. Exercise capacity and quality of life are worse than in other complex cyanotic
    congenital heart disease.
  notes: >
    Right heart failure is the leading cause of death, with sudden cardiac death and
    infection next. Pregnancy carries very high maternal mortality and is contraindicated.
    Non-cardiac surgery is also high-risk. Pulmonary vasodilator therapy has improved
    functional capacity and quality of life, but a systematic review correcting for
    immortal time bias found no improvement in survival among treatment-naive patients
    across four decades, so the burden should not be read as historical.
  evidence:
  - reference: PMID:39711759
    reference_title: "Update on Eisenmenger syndrome - Review of pathophysiology and recent progress in risk assessment and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Once these biases were accounted for, 10-year survival for contemporary patients with ES was 57 % in the overall cohort and 34 % in patients naïve to disease targeting therapy (DTT)"
    explanation: Contemporary bias-corrected survival figures.
  - reference: PMID:9556469
    reference_title: "The Eisenmenger syndrome in adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pregnancy or noncardiac surgery is associated with a high mortality rate in patients with the Eisenmenger syndrome."
    explanation: Establishes both pregnancy and non-cardiac surgery as high-mortality exposures.
  - reference: PMID:34616573
    reference_title: "High Maternal Neonatal Mortality and Morbidity in Pregnancy with Eisenmenger Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pregnancy complications found include preterm birth (78%), low birthweight (94%), intrauterine growth restriction (55%), oligohydramnios (16%), severe preeclampsia (33%), and placenta previa (5.5%)."
    explanation: Retrospective cohort of 18 pregnancies quantifying the obstetric complication burden.
  - reference: PMID:20439122
    reference_title: "Exercise performance and quality of life is more impaired in Eisenmenger syndrome than in complex cyanotic congenital heart disease with pulmonary stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Exercise performance and quality of life is more impaired in Eisenmenger syndrome than in complex cyanotic congenital heart disease with pulmonary stenosis"
    explanation: Comparative evidence that the functional burden exceeds that of other complex cyanotic congenital heart disease.
  - reference: PMID:11923814
    reference_title: "Poor prognosis and related factors in adults with Eisenmenger syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Survival rate was 98% at 1 year, 77% at 5 years, and 58% at 10 years, with the Kaplan-Meier method. Elevated right atrial pressure (>7 mm Hg) and reduced systemic blood flow (<2.9 L/min) were independently associated with increased mortality rate of adults with Eisenmenger syndrome."
    explanation: Cohort of 106 adults diagnosed in adulthood giving survival figures and two independent haemodynamic mortality predictors.
  - reference: PMID:40204597
    reference_title: "Risk stratification in Eisenmenger syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The only multivariable death risk-stratification model based on non-invasive predictors (age, shunt location, resting oxygen saturation, sinus rhythm and pericardial effusion) proposed thus far in Eisenmenger syndrome is awaiting external validation."
    explanation: Records that no externally validated risk score exists for this disease, so the prognostic markers curated here should be read as associations rather than as a usable score.
  - reference: PMID:40204597
    reference_title: "Risk stratification in Eisenmenger syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Several risk factors have been identified as independent predictors in Eisenmenger syndrome, including the 6-minute walk distance, echocardiographic markers and serum brain natriuretic peptide."
    explanation: Names the independent prognostic predictors, including the natriuretic peptide curated under biochemical.
discussions:
- discussion_id: treat_and_repair_strategy
  prompt: >
    Can aggressive pulmonary vasodilator therapy render an inoperable Eisenmenger patient
    operable, and should the defect then be closed?
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - pathophysiology#Right-to-left shunt as a protective right ventricular pop-off
  rationale: >
    The established position is that shunt closure must be avoided once Eisenmenger
    physiology exists, because the shunt is decompressing the right ventricle. The
    treat-and-repair strategy proposes that pulmonary vasodilators can lower pulmonary
    vascular resistance enough in selected responders to make closure safe again. Case
    series report good short- and medium-term outcomes, but there is no randomised
    evidence, no long-term follow-up, and no agreed haemodynamic threshold for
    eligibility. The stakes are asymmetric: closing the defect in a patient whose
    resistance does not stay down removes the pop-off irreversibly.
  proposed_experiments:
  - experiment_id: exp_es_treat_and_repair_registry
    name: Prospective multicentre registry of treat-and-repair with predefined haemodynamic eligibility
    description: >-
      Enrol patients with pulmonary arterial hypertension associated with congenital heart
      disease who meet a predefined post-treatment haemodynamic threshold, record whether
      closure was performed, and follow right ventricular function, functional class, and
      survival for at least five years against a matched non-closed comparison group.
    decision_criterion: >-
      Sustained right ventricular function and survival at five years in closed patients,
      relative to matched unclosed controls, would justify a threshold-based
      recommendation; deterioration would confirm the current avoid-closure default.
  evidence:
  - reference: PMID:33853494
    reference_title: "Preventing disease progression in Eisenmenger syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Once Eisenmenger syndrome develops, shunt closure should be avoided."
    explanation: States the default position that the treat-and-repair strategy proposes to qualify.
notes: >
  No GeneReviews chapter exists for Eisenmenger syndrome; a PubMed search for
  "Eisenmenger GeneReviews[All Fields]" returned no results, which is expected because the
  syndrome is an acquired physiologic end-state of a congenital lesion rather than a
  Mendelian disorder. Genetic content here is confined to susceptibility (BMPR2) and
  chromosomal risk (trisomy 21), both curated as modifiers of progression rather than
  causes.


  No `has_subtypes` block is curated, deliberately. Risk of progression is strongly
  lesion-dependent — nearly all unrepaired truncus arteriosus, roughly half of large
  ventricular septal defects, and under a tenth of large atrial septal defects — but that
  variation is a property of the *underlying congenital defect*, not of Eisenmenger
  syndrome itself. Once the physiology is established the entity is the same regardless
  of which defect produced it, so splitting by lesion would model the antecedent rather
  than the disease. The one place lesion identity does change management, transplant
  strategy selection, is curated on the transplantation treatment instead. Shunt level
  (pre- versus post-tricuspid) is carried in the trigger node description.


  One reference fetched during curation is deliberately left uncited: PMID:28566473
  (declining incidence and prevalence of Eisenmenger syndrome) is a Heart editorial
  comment whose PubMed record carries no abstract text, so no verifiable snippet can be
  quoted from it. The same epidemiological decline is curated from PMID:39711759 instead,
  which states it in quotable form.
datasets:
- accession: geo:GSE126322
  title: Remodeling of active endothelial enhancers is associated with aberrant gene-regulatory networks in pulmonary arterial hypertension [ChIP-seq]
  description: >-
    Chromatin profiling (H3K27ac, H3K4me1, H3K4me3 ChIP-seq) of pulmonary arterial
    endothelial cells extracted from the lungs of 10 patients with pulmonary arterial
    hypertension and 9 controls, showing large-scale remodeling of the active enhancer
    landscape while promoters and gene expression were unchanged.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: CHIP_SEQ
  sample_count: 55
  conditions:
  - pulmonary arterial hypertension
  - control
  platform: ChIP-seq of H3K27ac, H3K4me1 and H3K4me3
  publication: PMID:32245974
  genes:
  - preferred_term: BMPR2
    term:
      id: hgnc:1078
      label: BMPR2
  notes: >-
    Relevance triage, stated plainly: this dataset contains NO Eisenmenger syndrome and no
    congenital heart disease samples. Its cohort is pulmonary arterial hypertension
    generally. It is included solely because this entry declares `conforms_to` against
    `pulmonary_vascular_remodeling#Pulmonary Endothelial Dysfunction and Impaired BMP
    Signaling`, and this is primary human pulmonary artery endothelial cell data for
    exactly that conformed node; it cannot support any Eisenmenger-specific claim, and no
    evidence item cites it. No Eisenmenger-specific transcriptomic, epigenomic, or
    proteomic dataset exists in GEO. All 12 candidates surfaced by dataset discovery were
    gene-only matches on BMPR2 with no congenital-heart-disease content, so this is the
    closest mechanistically relevant primary dataset rather than a disease match.

📚

References & Deep Research

Deep Research

1

Claude Code ▸

Eisenmenger Syndrome: Comprehensive Research Report

claude-haiku-4-5-20251001, claude-sonnet-5 44 citations 2026-08-09T19:50:57.162190

Eisenmenger Syndrome: Comprehensive Research Report

1. Disease Information

Overview. Eisenmenger syndrome (ES) is the most advanced form of pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD). It describes the end-stage physiology that develops when a large, long-standing, unrestricted communication between the systemic and pulmonary circulations (at the aortopulmonary, ventricular, or atrial level) produces chronic high-flow/high-pressure exposure of the pulmonary vasculature, driving progressive pulmonary vascular remodeling, severe pulmonary vascular resistance (PVR) elevation, and eventual reversal of the shunt from left-to-right to right-to-left (or bidirectional), producing chronic systemic hypoxemia and cyanosis. First described by Paul Wood in 1958, ES is defined operationally as "pulmonary hypertension due to a high pulmonary vascular resistance with reversed or bidirectional shunt" occurring in the presence of a non-restrictive aortopulmonary, ventricular, or atrial communication (Banerjee & Opotowsky, 2024, PMID:39711759).

Key identifiers: - MONDO: MONDO:0019944 (Eisenmenger syndrome/complex) - Orphanet: ORPHA:97214 - ICD-10-CM: I27.83 (Eisenmenger's syndrome — pulmonary heart disease; code also the underlying defect, e.g., Q21.8 "Eisenmenger's defect," or the specific septal defect code) - MeSH: D004466 (Eisenmenger Complex) - NCIT candidate treatment-action anchor: NCIT:C15986 (Pharmacotherapy), NCIT:C15329 (Surgical Procedure) — for downstream annotation of PAH-targeted drugs and transplantation

Synonyms/alternative names: Eisenmenger complex; Eisenmenger reaction; Eisenmenger physiology; pulmonary hypertension due to congenital systemic-to-pulmonary shunt with reversed/bidirectional shunt.

Nature of evidence base: Because ES is a rare, heterogeneous, acquired physiologic end-state of multiple distinct congenital cardiac lesions (rather than a single monogenic disorder), the literature is predominantly aggregated disease-level and cohort-level clinical evidence — multicenter and single-center adult congenital heart disease (ACHD) registries (e.g., the Euro Heart Survey, UK/Royal Brompton cohorts, COMPERA-CHD), randomized controlled trials of PAH-targeted therapy (e.g., BREATHE-5, EIGER, the bosentan-sildenafil combination RCT), and case series/case reports for rarer complications (pregnancy, transplantation). There is essentially no individual-patient EHR-derived "N-of-1" data source specific to ES as such; genetic data (e.g., BMPR2 mutation carriage) come from smaller mechanistic/candidate-gene cohorts nested within PAH-CHD research rather than population biobanks.

2. Etiology

2a. Disease Causal Factors (mechanistic/anatomic)

ES is not itself a primary genetic disease but the pathophysiological consequence of an untreated congenital systemic-to-pulmonary shunt. The causal chain is: 1. A non-restrictive congenital cardiac communication (VSD, ASD, AVSD, PDA, truncus arteriosus, or a complex/univentricular lesion with unobstructed pulmonary flow) permits chronic left-to-right shunting. 2. Persistently elevated pulmonary blood flow and/or pressure produces shear-stress-mediated pulmonary endothelial dysfunction, triggering progressive pulmonary vascular remodeling (vasoconstriction → medial hypertrophy → intimal proliferation/fibrosis → in situ thrombosis → plexiform arteriopathy). 3. Rising PVR eventually equals or exceeds systemic vascular resistance, reversing (or making bidirectional) the shunt — the defining moment of "Eisenmenger physiology" — producing chronic hypoxemia/cyanosis (PMC11658362, PMID:39711759; StatPearls NBK507800).

Lesion-specific risk of progression to ES (StatPearls; JACC 2008 review, PMID:19245962): - Truncus arteriosus: nearly all unrepaired cases progress - Large unrepaired VSD: ~50% (aortopulmonary or ventricular-level shunts overall 52–53% in Euro Heart Survey data) - Large unrepaired PDA: substantial risk, especially with continuous high-pressure exposure - Large unrepaired ASD: only ~9–10% (because pressure, not just flow, is transmitted less directly at the atrial level) — this lower-penetrance group is where a genetic susceptibility factor (e.g., BMPR2) is thought to matter most, since hemodynamic stress alone is often insufficient (ScienceDirect, PMID:27002414).

2b. Risk Factors

Genetic risk factors: - BMPR2 mutations — heterozygous loss-of-function variants in the TGF-β/BMP type II receptor gene, the classic cause of heritable/idiopathic PAH, are also found at increased rate in PAH-CHD/Eisenmenger cohorts. One cohort found a 12.6% BMPR2 mutation rate in "repaired" CHD-associated pulmonary vascular disease patients (i.e., those who develop PAH despite/after defect closure), with missense variants predominating and a higher detection rate in females and repaired patients (Zhu et al., PMID:27002414). BMPR2 is proposed as "a potential predisposing genetic risk factor" that lowers the threshold for hemodynamic-stress-induced pulmonary vascular disease, but the relationship is not absolute — ASD-associated Eisenmenger physiology can occur without any detectable BMPR2 mutation, implying other genetic contributors (PMID:17102831). - Other BMP/TGF-β pathway genes implicated in PAH broadly (and plausibly relevant modifiers in PAH-CHD): ACVRL1/ALK1, ENG (endoglin), SMAD1, SMAD4, SMAD9, SMAD5, SOX17 — variants (including de novo changes) have been reported in APAH-CHD cohorts (Springer Pediatric Cardiology review, 2025). - Trisomy 21 (Down syndrome, HGNC gene dosage effect, not single-gene) — a well-established genetic factor that accelerates progression to pulmonary vascular obstructive disease/Eisenmenger physiology independent of lesion type, historically producing ES at much younger ages and higher rates when surgery was delayed (PMID:27325590). - Standard clinical genetic screening for suspected heritable PAH contribution focuses on sequencing BMPR2, ALK1 (ACVRL1), Endoglin (ENG), and SMAD9.

Environmental/clinical risk factors: - Delayed or absent surgical repair of the underlying shunt lesion — the single largest modifiable risk factor. Repair within the first ~2 years of life largely prevents ES. - Post-tricuspid (ventricular-level or great-vessel-level) shunt location vs. pre-tricuspid (atrial-level) — post-tricuspid shunts transmit pressure directly to the pulmonary circuit and confer much higher ES risk. - Limited access to healthcare/diagnostic services — geographic/socioeconomic disparity is a major real-world driver; ES is now largely a disease of resource-limited settings, since early detection and closure have reduced its prevalence by ~50% over 50 years in the developed world (PMID:28566473). - High altitude residence — chronic hypoxic pulmonary vasoconstriction is understood to exacerbate pulmonary vascular disease progression (cited as an aggravating/avoidance factor in management guidance; StatPearls NBK507800). - Female sex and repaired-CHD status correlate with higher detected BMPR2 mutation rates in the cited cohort, suggesting a possible sex-genetic interaction, though data are limited.

2c. Protective Factors

Early corrective/palliative cardiac surgery (within the first 1–2 years of life) is the dominant protective intervention and has driven the measured decline in ES incidence in high-resource countries.
Improved perinatal/pediatric screening (prenatal echocardiography, newborn pulse-oximetry screening) enabling earlier defect detection.
No specific protective genetic variant has been characterized for ES to date (unlike some diseases with described protective alleles); this remains an evidence gap.

2d. Gene-Environment Interactions

The clearest documented gene-environment interaction is that hemodynamic stress (the "environmental"/mechanical exposure of chronic shunt flow) is necessary but not sufficient to cause severe irreversible pulmonary vascular disease in many patients — a genetic susceptibility factor (BMPR2 or other BMP-pathway variant) appears to lower the flow/pressure threshold required to trigger irreversible remodeling, explaining why only a minority of patients with a given anatomic lesion (e.g., ~9–53% depending on lesion type) progress to ES despite similar shunt anatomy (PMID:27002414, PMID:17102831). Down syndrome (a genetic dosage state) similarly interacts with shunt-lesion "exposure" to accelerate the same final pathway.

3. Phenotypes

Symptoms / Clinical Signs (HP-mappable)

Phenotype	Suggested HPO term	Frequency/notes
Exertional dyspnea	HP:0002875 (Exertional dyspnea)	Most frequent presenting symptom
Central cyanosis	HP:0007204 (Central cyanosis) / HP:0000961 (Cyanosis)	Cardinal, progressive feature; onset usually childhood–young adulthood as shunt reverses
Digital clubbing	HP:0100759 (Nail clubbing)	Common, more pronounced in lower extremities with PDA-associated ES ("differential clubbing/cyanosis")
Syncope	HP:0001279 (Syncope)	Poor prognostic marker at presentation
Palpitations	HP:0001962 (Palpitations)	Reflects atrial/ventricular arrhythmia
Hemoptysis	HP:0002105 (Hemoptysis)	From pulmonary infarction, vessel rupture, or coagulopathy; historically a leading cause of death, now 5th most common (post-DTT era)
Fatigue/lethargy	HP:0012378 (Fatigue)	Nonspecific but near-universal
Chest pain	HP:0100749 (Chest pain)	Can reflect pulmonary infarction or ischemia
Right heart failure signs (edema, ascites, hepatomegaly)	HP:0000969 (Edema), HP:0001541 (Ascites), HP:0002240 (Hepatomegaly)	Progressive/late-stage; leading contemporary cause of death
Headache/dizziness/visual changes (hyperviscosity)	HP:0002315 (Headache), HP:0002321 (Vertigo)	From secondary erythrocytosis/hyperviscosity
Gout	HP:0002804 (Joint hyperflexibility — not exact; better: HP:0001997 Gout)	From hyperuricemia (increased RBC turnover)
Cholelithiasis	HP:0001081 (Cholelithiasis)	From chronic hyperbilirubinemia (hemolysis/RBC turnover)
Hypertrophic osteoarthropathy	HP:0040217 (Hypertrophic pulmonary osteoarthropathy candidate)	Associated with chronic cyanosis
Stroke/TIA	HP:0001297 (Stroke)	Paradoxical embolism or thrombotic; cerebral abscess also reported
Brain abscess	HP:0100738 (Brain abscess)	From right-to-left shunt bypassing pulmonary filtration of septic emboli
Nephropathy/proteinuria	HP:0000093 (Proteinuria)	Reported in up to 30% (proteinuria) / ~60% (albuminuria) of cyanotic patients

Onset, Severity, Progression, Frequency

Age of onset: Highly lesion-dependent. Post-tricuspid shunts (large VSD, PDA, truncus arteriosus, AVSD, especially with trisomy 21) can progress to irreversible pulmonary vascular disease and shunt reversal in infancy to early childhood; pre-tricuspid shunts (ASD) typically manifest ES only in the third or fourth decade of life or later.
Severity/progression: Progressive and generally irreversible once established; three histopathologic stages of the underlying vasculopathy (vasoconstriction → remodeling → thrombosis) parallel worsening clinical severity, culminating in NYHA functional class decline, right heart failure, and death. Overall disease course is chronic and progressive, though the rate varies widely by underlying lesion complexity.
Frequency among CHD patients: ~8% of all congenital heart disease patients develop ES; historically 17.5% (Wood, 1958) versus 1–5.7% in contemporary high-resource registries (e.g., 5.7% of 4,110 adults in the Euro Heart Survey), reflecting the impact of early surgical repair (PMID:39711759; PMID:28566473).

Quality of Life

Quality of life is markedly and disproportionately impaired compared with other cyanotic CHD groups: exercise performance and QoL are more impaired in ES than in complex cyanotic CHD with pulmonary stenosis (PMID:20439122), with peak oxygen uptake reduced ~45% and ventilatory equivalent for CO₂ ~70% higher than healthy controls. Most patients function in NYHA/WHO functional class II–III. PAH-targeted drug therapy (e.g., sildenafil) has been shown to significantly improve QoL and functional class in randomized and observational studies (PMID:20304507).

4. Genetic/Molecular Information

Causal genes (susceptibility, not strictly Mendelian-causal for the syndrome itself): - BMPR2 (HGNC:1078; OMIM 600799) — bone morphogenetic protein receptor type 2; loss-of-function/missense variants; the canonical heritable-PAH gene, also implicated as a susceptibility modifier in PAH-CHD/ES (PMID:27002414). - ACVRL1/ALK1 (HGNC:175) and ENG (HGNC:3349) — activin receptor-like kinase 1 and endoglin, both BMP9/10 co-receptor components; classically hereditary hemorrhagic telangiectasia genes, also linked to PAH. - SMAD1, SMAD4, SMAD5, SMAD9 (downstream BMP-pathway transcription factors) — variants reported in APAH-CHD, including de novo changes. - SOX17 — increasingly recognized PAH-CHD-associated gene.

Variant classification/type: Predominantly missense (dominant, likely haploinsufficiency mechanism for BMPR2); variant pathogenicity should be interpreted per ACMG/AMP criteria via ClinVar/ClinGen. Functional consequence is generally loss of function in the BMP/TGF-β signaling receptor complex, disinhibiting proliferative/anti-apoptotic signaling in pulmonary vascular smooth muscle and endothelium.

Population frequency: Rare variants; population allele frequency data should be checked against gnomAD for any specific variant before curation (no ES-specific germline founder variant has been established).

Somatic vs. germline: Germline (constitutional) — these are inherited/de novo susceptibility alleles, not somatic mutations.

Chromosomal abnormality: Trisomy 21 (Down syndrome) is the principal chromosomal risk factor, present in a substantial minority of ES patients with AVSD/VSD, and independently associated with accelerated pulmonary vascular disease.

Epigenetics: No ES-specific DNA methylation/histone signature has been well characterized in the literature reviewed; this is a knowledge gap. (Broader PAH literature does describe epigenetic dysregulation, e.g., of BMPR2 and HIF pathways, but ES-specific data are sparse — flag as KNOWLEDGE_GAP if curating.)

Suggested gene/ontology annotations: - Gene: hgnc:1078 (BMPR2), hgnc:175 (ACVRL1), hgnc:3349 (ENG), hgnc:11177 (SMAD9) - GO biological process: GO:0030510 (regulation of BMP signaling pathway), GO:0001525 (angiogenesis), GO:0003085 (negative regulation of systemic arterial blood pressure — context-dependent)

5. Environmental Information

Environmental/exposure factors: No toxin, pollutant, or occupational exposure is established as causal for ES; the "environmental" driver is fundamentally mechanical/hemodynamic (chronic high pulmonary flow/pressure from the unrepaired shunt) rather than a chemical or infectious agent.
Lifestyle factors relevant to management (not causation): Dehydration, isometric exercise, high-altitude exposure, and iron deficiency are all specifically flagged in clinical guidance as conditions to avoid because they exacerbate hyperviscosity/hypoxemia physiology in established ES (StatPearls NBK507800). Suggested ECTO terms would apply to "exposure to high altitude" as an exacerbating (not causal) factor.
Infectious agents: Not causal, but infective endocarditis is a major secondary complication given the intracardiac shunt and turbulent flow, with risk of septic paradoxical embolization to the brain (abscess) or systemic circulation because right-to-left shunting bypasses the normal pulmonary filtration of septic emboli.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream)

Trigger (MOLECULAR/TISSUE scale): Chronic elevated pulmonary blood flow and/or pressure from a non-restrictive systemic-to-pulmonary shunt imposes abnormal shear stress on the pulmonary vascular endothelium.
Endothelial dysfunction (MOLECULAR/CELLULAR): Dysfunctional pulmonary-artery endothelial cells show decreased production of prostacyclin (PGI2) and endogenous nitric oxide (via eNOS dysfunction), together with increased endothelin-1 (ET-1) production — an imbalance that favors vasoconstriction and smooth-muscle proliferation. Elevated thromboxane A2, platelet activation, and increased intrinsic elastase and vascular endothelial growth factor (VEGF) production further drive pathological remodeling (JACC 2008 review PMID:19245962; PMC11658362).
Vascular remodeling (TISSUE): Progressive structural changes follow the classic Heath-Edwards histopathological grading (1958):
Grade I: medial hypertrophy of small muscular arteries/arterioles
Grade II: + intimal cellular proliferation (smooth muscle migration to subendothelium)
Grade III: + advanced medial thickening, progressive intimal fibrosis, arteriolar obliteration
Grade IV: plexiform lesions — focal proliferation of endothelial-lined channels within dilated arterial segments
Grade V: complex plexiform, angiomatous, and cavernous lesions with hyalinizing intimal fibrosis
Hemodynamic consequence (ORGANISM): Rising pulmonary vascular resistance eventually equals/exceeds systemic vascular resistance, reversing the shunt from left-to-right to bidirectional/right-to-left — the defining Eisenmenger transition — producing chronic arterial hypoxemia.
Systemic downstream consequences (ORGANISM): Chronic hypoxemia triggers secondary/compensatory erythrocytosis (renal erythropoietin-driven), which can be blunted by iron deficiency; hyperviscosity with thrombotic/hemorrhagic diathesis; multiorgan effects including renal dysfunction (proteinuria/albuminuria, reduced GFR), gout (hyperuricemia from increased cell turnover), cholelithiasis (hyperbilirubinemia), hypertrophic osteoarthropathy, and neurologic events (paradoxical embolism, cerebral abscess, hemorrhagic/ischemic stroke).
Cardiac remodeling and arrhythmia (TISSUE/ORGANISM): Chronic right ventricular pressure/volume overload leads to right heart failure over time; atrial arrhythmias (notably atrial fibrillation, conferring an ~11.45-fold increased sudden cardiac death risk in multivariate analysis), conduction disease, and ventricular arrhythmia contribute to sudden cardiac death — the second/third leading cause of mortality in the contemporary era (AHA/JAHA PMID via PMC7335528).

Cell types and biological processes involved

Pulmonary artery endothelial cells (CL:0002544 or general endothelial cell CL:0000115) — dysfunction is the initiating cellular lesion.
Pulmonary artery vascular smooth muscle cells (CL:0000359) — undergo hyperplasia/hypertrophy and migration into the intima.
Platelets — activation contributes to in situ thrombosis and to the bleeding/thrombosis diathesis.
Renal cells (erythropoietin-producing interstitial fibroblasts) — drive compensatory erythropoiesis.
Relevant GO biological processes: GO:0001525 (angiogenesis), GO:0043615 (astrocyte cell migration — not relevant), better: GO:0090023 (positive regulation of neutrophil chemotaxis — not relevant); most relevant: GO:0001974 (blood vessel remodeling), GO:0043491 (protein kinase B signaling — pathway adjacent), GO:0007179 (TGF-beta receptor signaling pathway, given BMPR2/ALK1 involvement), GO:0038063 (T cell extravasation — not relevant). Core recommended terms: GO:0001974 (blood vessel remodeling), GO:0007179 (transforming growth factor beta receptor signaling pathway), GO:0001525 (angiogenesis).

Suggested downstream/module conformance

This pathophysiology is closely analogous to the dismech pulmonary_vascular_remodeling module (HP:0002092, obstructive pulmonary vascular remodeling driving PAH with RV overload) and shares upstream endothelial-dysfunction biology with the general vascular-remodeling literature; ES-specific curation should model it as a CHD-triggered variant of that chain, with the shunt-reversal node as the key discriminating causal step versus idiopathic/heritable PAH.

7. Anatomical Structures Affected

Organ level: - Primary: Heart (all chambers, especially right ventricle and atria) and pulmonary arterial vasculature (UBERON:0002012 pulmonary artery; UBERON:0000948 heart) - Secondary/systemic: Kidneys (proteinuria, reduced GFR), liver/biliary tree (cholelithiasis from hyperbilirubinemia), joints (gout), bone/periosteum (hypertrophic osteoarthropathy), central nervous system (stroke, brain abscess), skin (plethora, acrocyanosis, livedo reticularis, ischemic ulceration), bone marrow (erythroid hyperplasia). - Body systems: Cardiovascular (primary), respiratory, renal, hepatobiliary, musculoskeletal, hematologic, neurologic.

Tissue/cell level: - Pulmonary arterial media, intima, and adventitia (site of Heath-Edwards remodeling grades I–V) - Right ventricular myocardium (hypertrophy/fibrosis from chronic pressure overload) - Bone marrow erythroid precursors (erythrocytosis)

Subcellular level (GO Cellular Component): - Endothelial cell plasma membrane (site of eNOS, ET-1 receptor signaling) - Mitochondria (implicated ROS accumulation contributing to endothelial dysfunction)

Localization: Bilateral, diffuse pulmonary vascular involvement (not lateralized); underlying cardiac defect location varies (septal — ventricular/atrial — vs. great vessel level for PDA/truncus arteriosus).

8. Temporal Development

Onset pattern: Insidious and progressive, beginning with an asymptomatic left-to-right shunt phase in infancy, transitioning through a variable latency period to shunt reversal. Onset of overt cyanosis/ES physiology ranges from infancy (post-tricuspid, high-pressure lesions, especially with trisomy 21) to the third or fourth decade (pre-tricuspid ASD-type lesions).
Stages: (1) Left-to-right shunt with normal/mildly elevated PVR; (2) progressive pulmonary vascular remodeling with rising PVR (potentially still surgically correctable "window" period); (3) fixed elevated PVR with bidirectional shunting (transitional); (4) established Eisenmenger physiology with right-to-left shunting and cyanosis (surgical correction now contraindicated).
Progression rate: Variable — lesion type and presence of accelerating factors (trisomy 21, larger defect, genetic susceptibility) determine rate; once ES is established, disease is chronic and progressive with intermittent stability punctuated by complications (arrhythmia, hemoptysis, heart failure decompensation).
Critical period for intervention: Cardiac repair in the first 2 years of life is the key window to prevent ES; beyond a certain threshold of fixed pulmonary vascular disease, defect closure becomes contraindicated because removing the "pop-off" right-to-left shunt in the face of severe fixed PVR precipitates acute right heart failure.
Remission: No spontaneous remission described; "treat and repair" (aggressive PAH-targeted therapy followed by defect closure in selected reversible cases) shows good short/medium-term outcomes in case series but lacks long-term outcome data and cannot yet be systematically recommended (PMID:39711759).

9. Inheritance and Population

Epidemiology: - ~8% of all CHD patients develop ES overall; historically 17.5% (Wood 1958 cohort) vs. 1–5.7% contemporary (Euro Heart Survey: 5.7% of 4,110 adults). - Orphanet prevalence estimate: 1–9 per 1,000,000 (ultra-rare). - By lesion: 52–53% of large aortopulmonary/ventricular-level shunts progress to ES vs. only ~9–10% of large atrial-level shunts. - Prevalence has declined ~50% over the past 50 years in developed countries due to early surgical repair (PMID:28566473), while remaining a larger relative burden in resource-limited regions with delayed diagnosis/access to cardiac surgery (e.g., a Yunnan, China pediatric CHD cohort study, PMID:35522268).

Inheritance pattern: ES itself is not a single-gene Mendelian disorder — it is an acquired physiologic consequence of an underlying (usually sporadic) congenital cardiac malformation, modified by susceptibility genetics (BMPR2 and related BMP-pathway variants, generally autosomal dominant with incomplete penetrance when causal for heritable PAH) and by chromosomal factors (trisomy 21). - Penetrance: Incomplete for BMPR2-type susceptibility variants — most CHD patients with a given lesion do NOT develop ES even without repair, implying gene-environment/dose interaction. - Founder effects / consanguinity / carrier frequency: Not well established specific to ES; the underlying CHD lesions themselves (e.g., AVSD in trisomy 21) have their own population genetics.

Population demographics: - Sex ratio: Reported as approximately equal (males and females equally affected), per NORD/GARD summaries, though BMPR2 mutation detection rate was higher in females in one cohort (PMID:27002414) and pregnancy-specific complications obviously affect female patients disproportionately in clinical impact. - Geographic distribution: Disproportionately represents populations with limited access to pediatric cardiac surgery — a "disease of health system gaps" in the modern era. - Age distribution: Adult survivors span young adulthood through middle age; median survival substantially reduced relative to the general population (see Section 11).

10. Diagnostics

Clinical/initial workup: - History and physical exam (cyanosis, clubbing, signs of right heart failure); note that loud murmurs may be absent because equalized right/left ventricular pressures minimize turbulent flow across the shunt — an important diagnostic pitfall (StatPearls NBK507800). - Pulse oximetry (resting and with exercise) - Chest radiograph, ECG, pulmonary function tests - Complete blood count and iron studies (to characterize secondary erythrocytosis and iron status) - Renal function, uric acid (annual monitoring recommended) - BNP/NT-proBNP (validated prognostic biomarker, more reliable than echocardiographic RVEF alone for prognosis; PMC5841908)

Imaging: - Echocardiography is the mainstay noninvasive tool: depicts the underlying anatomic lesion, shunt site/direction (color Doppler demonstrating right-to-left or bidirectional flow), pulmonary artery pressure estimation, right heart size/function (e.g., TAPSE <15 mm associated with adverse outcomes). - Cardiac MRI: assesses RV size/function and myocardial fibrosis — native T1/extracellular volume (ECV) mapping; an ECV threshold of ~29.0% discriminated high-risk from lower-risk patients (AUC 0.857) in one cohort. - Right heart catheterization remains the gold-standard confirmatory test, providing direct measurement of pulmonary artery pressure, PVR, saturations at each chamber, and (where relevant) pulmonary vasoreactivity testing to assess for any residual operability.

Genetic testing: Not routine for sporadic ES, but consider sequencing BMPR2, ACVRL1 (ALK1), ENG, SMAD9 when heritable PAH is suspected (e.g., family history of PAH, disproportionate severity relative to lesion, or ASD-type ES without adequate hemodynamic explanation) — a scenario explicitly documented in case reports (e.g., PMC5742392, genetic analysis in a patient with severe PAH and ASD undergoing lung transplantation).

Differential diagnosis: Other causes of pulmonary hypertension/right-to-left shunting must be excluded, including connective tissue disease (scleroderma, MCTD, SLE)-associated PAH, chronic viral infection (HIV, hepatitis B/C)-associated PAH, and idiopathic/heritable PAH without a structural shunt.

Screening: No population screening program exists for ES specifically; prevention operates through prenatal and neonatal CHD screening (fetal echocardiography, newborn pulse-oximetry screening for critical CHD) that enables early corrective surgery before irreversible pulmonary vascular disease develops.

11. Outcome/Prognosis

Survival: - Contemporary cohort data (adjusting for prior survivorship biases): 57% 10-year survival in the overall ES cohort and 34% 10-year survival in patients naïve to disease-targeting PAH therapy (PMC11658362/PMID:39711759). - Other reported figures: 98% at 1 year, 77% at 5 years, 58% at 10 years in one series; survival to age 40/50/60 of 94%/74%/52% in another. - Historical estimates (pre-modern-therapy era): ~70–80% 10-year survival, 42% 25-year survival. - Median survival is reduced by approximately 20 years compared with the general population, and is worst in patients with complex/multiple lesions. - Notably, ES patients have better survival than adults with idiopathic PAH with comparable hemodynamics, attributed to the protective "pop-off" effect of the right-to-left shunt decompressing the right ventricle.

Causes of death (contemporary/disease-targeted-therapy era, in descending order): 1. Right heart failure (leading cause, unchanged across eras) 2. Sudden cardiac death 3. Arrhythmia 4. Hemoptysis (declined from 3rd to 5th most common with modern management) 5. Hemorrhage (~7.3% of known deaths); thromboembolism ~8.3% of known deaths

Predictors of poor prognosis: History of syncope, elevated mean right atrial pressure (≥8 mmHg), systemic arterial desaturation <85%, older age, pre-tricuspid shunt location, low resting SpO2, absence of sinus rhythm, pericardial effusion, reduced 6-minute walk distance, atrial fibrillation (11.45-fold increased SCD risk), QRS duration ≥120 ms (2.06-fold increased SCD risk), complete heart block, right bundle branch block, right atrial enlargement, elevated NT-proBNP, TAPSE <15 mm, low serum albumin/potassium, high cardiac MRI ECV (>29%).

Morbidity/QoL: Substantially reduced exercise capacity (peak VO2 ~45% lower than controls) and QoL, worse than in other complex cyanotic CHD groups; complications include thromboembolic and hemorrhagic events, renal impairment (proteinuria in up to 30%, albuminuria up to 60% of cyanotic patients), gout, cholelithiasis, hypertrophic osteoarthropathy, and neurological events.

Special outcome context — pregnancy: Absolute contraindication to pregnancy; maternal mortality 30–50% (up to 65% with cesarean section), with 70% of deaths occurring in the postpartum period (days 2–30) or peripartum; major causes include hypovolemia, thromboembolism, and preeclampsia.

Transplantation outcomes: Heart-lung transplantation provides the best outcomes among transplant strategies for VSD-associated ES (1-, 5-, 10-year survival of 72.6%, 51.3%, 27.6%); for ASD-associated ES, bilateral lung transplant with cardiac defect repair may offer superior outcomes to combined heart-lung transplant. Median survival post-transplant: 7.4 years (heart-lung) vs. 1.1 years (isolated lung transplant, per one comparative study) — though these figures should be interpreted cautiously given selection bias in small cohorts.

12. Treatment

Pharmacotherapy (PAH-targeted "disease-targeting therapy," DTT)

Endothelin receptor antagonists (ERAs): Bosentan — demonstrated in the BREATHE-5 RCT to significantly improve hemodynamics and exercise capacity without worsening oxygen saturation in WHO FC III ES patients (short- and long-term). Macitentan (MAESTRO trial) showed no clear benefit in less advanced disease.
PDE-5 inhibitors: Sildenafil and tadalafil — improve exercise capacity, functional class, hemodynamics, and QoL (PMID:20304507).
Prostanoids: Inhaled iloprost (EIGER study, PMID:24012036) improves 6MWD, QoL, RV function; IV epoprostenol and subcutaneous treprostinil improve hemodynamics/saturation/exercise capacity; selexipag shows benefit in case series.
Soluble guanylate cyclase stimulator: Riociguat — no ES-specific RCT, but subgroup PAH-CHD data show sustained 2-year improvement.
Combination therapy (e.g., bosentan + sildenafil, RCT PMID via academic.oup.com/eurheartj/31/9/1124): registry data show improved survival on dual therapy vs. monotherapy, though confounded by indication in observational studies.
Heart failure adjuncts: No proven mortality benefit for digoxin, ACE inhibitors, or ARBs; beta-blockers show a benefit approaching statistical significance; SGLT2 inhibitors/ARNi/MRA remain unstudied in ES specifically.
Anticoagulation: Not routinely recommended absent a specific thromboembolic indication, given the coexisting bleeding diathesis; no demonstrated survival benefit.

Advanced/procedural therapies

Intrathoracic organ transplantation (heart-lung or bilateral lung + defect repair) — the only intervention that can meaningfully improve survival/QoL in advanced disease, though limited by donor availability and surgical risk (higher perioperative bleeding).
"Treat and repair" strategy — aggressive PAH-targeted medical therapy followed by surgical defect closure in carefully selected, hemodynamically responsive patients; promising early/medium-term case-series outcomes but not yet a standard, systematically recommended pathway.
Surgical closure of the underlying defect is contraindicated once severe, fixed (non-reversible) PAH/Eisenmenger physiology is established, since the shunt is protectively decompressing the right ventricle.

Supportive care

Correction of iron deficiency (careful — avoid routine venesection/phlebotomy, which worsens iron deficiency and increases stroke risk despite historical practice); phlebotomy/apheresis reserved for hemoglobin >22 g/dL with confirmed hyperviscosity symptoms after excluding dehydration/other mimics.
Endocarditis prophylaxis, IV line air filters, avoidance of dehydration/isometric exercise/high altitude/iron deficiency.
Exercise training as an adjunct to optimal medical therapy — shown safe and beneficial for 6MWD, QoL, peak VO2, and symptoms in the PAH-CHD/ES population.
Genetic counseling for families where a heritable PAH-pathway variant is identified.

Experimental

Ongoing trials of macitentan (NCT01739400, long-term safety/tolerability) and other agents in ES-specific populations, tracked via ClinicalTrials.gov.

Suggested NCIT treatment terms

NCIT:C15986 (Pharmacotherapy) as the generic action, with therapeutic_agent bound to CHEBI terms for bosentan, sildenafil, tadalafil, iloprost, epoprostenol, treprostinil, selexipag, riociguat, macitentan.
NCIT:C15289 (Organ Transplantation) for heart-lung/lung transplantation.
NCIT:C15329 (Surgical Procedure) for defect closure (in the pre-Eisenmenger or "treat-and-repair" window only).

13. Prevention

Primary prevention: Timely surgical or catheter-based closure of the underlying congenital shunt lesion, ideally within the first 1–2 years of life, before irreversible pulmonary vascular remodeling occurs. This is by far the most effective preventive strategy and underlies the observed ~50% decline in ES prevalence over 50 years in resource-rich settings.
Secondary prevention/early detection: Prenatal fetal echocardiography and newborn pulse-oximetry screening for critical CHD enable earlier diagnosis and timely surgical referral, particularly important in high-risk groups such as infants with Down syndrome and AVSD, where the historic progression rate to ES fell from 53% (1950s/60s birth cohort) to 0.5% (2000–2009 birth cohort) with improved early surgical intervention (ResearchGate/PMID:27325590 summary).
Tertiary prevention (in established ES): Endocarditis prophylaxis, avoidance of precipitants (dehydration, high altitude, isometric exercise, iron deficiency), correction of iron deficiency without inappropriate venesection, annual laboratory monitoring (CBC, iron studies, renal function, uric acid), pregnancy avoidance/contraception counseling, and early initiation of PAH-targeted therapy to reduce sudden cardiac death and heart failure risk.
Genetic counseling: Recommended for families with a heritable PAH-pathway variant (BMPR2 or related gene) identified in a proband, given autosomal dominant inheritance with incomplete penetrance.
Public health: Improving global access to pediatric cardiac surgery and diagnostic imaging is explicitly identified in the literature as the single most impactful public-health lever, since "the majority of children at risk globally will have a reparable heart defect" and timely access "would eliminate the vast majority of suffering, disability, and death from Eisenmenger syndrome" (StatPearls NBK507800).

14. Other Species / Natural Disease

Taxonomy: Naturally occurring "Eisenmenger physiology" (shunt reversal with pulmonary hypertension) is well documented in domestic dogs (Canis lupus familiaris, NCBITaxon:9615) and cats, most classically in the context of patent ductus arteriosus (PDA) that goes unrecognized/untreated.
Natural disease/veterinary relevance: In dogs with bidirectionally or continuously right-to-left shunting PDA, "Eisenmenger's (patho-)physiology" is the standard veterinary term for the same shear-stress-driven pulmonary vascular remodeling → shunt reversal sequence described in humans, with clinical presentation of cyanosis, polycythemia, and congestive heart failure (Greet et al., JVIM 2021; dvm360 review). One reported dog colony showed pulmonary hypertension and shunt reversal developing within the first few weeks of life, closely paralleling the accelerated human pediatric (e.g., trisomy 21) phenotype, making canine PDA populations a naturally occurring comparative model.
Comparative biology: The pathophysiological cascade (endothelial shear stress → reactive vasoconstriction → medial hypertrophy → intimal proliferation → shunt reversal) is conserved between species, supporting the general mechanistic model. Differential clubbing/cyanosis (more pronounced in caudal versus cranial body regions) is a distinguishing clinical sign in PDA-associated reverse shunting in both species, reflecting the anatomic level of the shunt relative to the origin of the great vessels.
Zoonotic potential: None — this is a hemodynamic/structural disease, not transmissible.

15. Model Organisms

In vivo surgical/flow models (primary experimental system used):
Rodent aortocaval fistula (ACF) model — a surgically created communication between the abdominal aorta and inferior vena cava in rats/mice reproduces the physiological and pathological hallmarks of CHD-associated PAH, including volume-overload-driven pulmonary vascular remodeling and matrix synthesis changes consistent with cyclic-stretch-mediated injury (PMC5870112; PMID:32630068). This is presented in the literature as a reliable platform for studying shunt-associated PAH mechanistically, though it models flow/volume overload generally rather than a specific congenital cardiac lesion.
This model is also used more broadly as a volume-overload congestive heart failure/cardiac hypertrophy model (Abassi et al., 2011), so findings related purely to cardiac remodeling (versus pulmonary vascular remodeling specifically) require careful interpretation.
Naturally occurring animal disease (see Section 14): Client-owned dogs with untreated/late-diagnosed PDA developing spontaneous Eisenmenger physiology represent a naturally occurring, non-induced comparative model, valuable because it arises without artificial surgical creation of the shunt and may better capture developmental/chronic aspects of pulmonary vascular remodeling.
Limitations: No established genetically engineered mouse model (e.g., conditional Bmpr2 knockout combined with a surgical shunt) specific to Eisenmenger-type PAH-CHD was identified in this search; most mechanistic PAH mouse genetics (Bmpr2+/- mice, Sugen/hypoxia models) model idiopathic/heritable PAH rather than CHD-shunt-driven PAH specifically, and translational fidelity to the shunt-reversal endpoint of true Eisenmenger physiology has not been systematically validated — this is a candidate HUMAN_MODEL_MISMATCH consideration for curation (rodent flow/volume-overload models reproduce vascular remodeling features but not the full congenital developmental context, and canine natural disease, while anatomically faithful, has not been mechanistically profiled to the same molecular depth as rodent models).
Applications: ACF and related shunt models are primarily used to study flow-mediated endothelial shear stress signaling, extracellular matrix remodeling, and candidate therapeutic responses (e.g., testing PAH-targeted drugs in a shunt-flow context) rather than to model the full multi-decade natural history or genetic susceptibility (BMPR2) interaction seen in humans.

Summary of Key Ontology Term Suggestions for Curation

Domain	Suggested term(s)
Disease	MONDO:0019944 (Eisenmenger syndrome); ORPHA:97214
Phenotypes	HP:0007204/HP:0000961 (cyanosis), HP:0100759 (clubbing), HP:0002875 (exertional dyspnea), HP:0002105 (hemoptysis), HP:0001279 (syncope), HP:0001997 (gout), HP:0001081 (cholelithiasis), HP:0001297 (stroke), HP:0100738 (brain abscess), HP:0000093 (proteinuria)
Genes	hgnc:1078 (BMPR2), hgnc:175 (ACVRL1), hgnc:3349 (ENG), hgnc:11177 (SMAD9)
GO biological process	GO:0001974 (blood vessel remodeling), GO:0007179 (TGF-beta receptor signaling pathway), GO:0001525 (angiogenesis)
Cell types	CL:0000115 (endothelial cell)/pulmonary artery endothelial cell, CL:0000359 (vascular smooth muscle cell)
Anatomy	UBERON:0002012 (pulmonary artery), UBERON:0000948 (heart), UBERON:0002113 (kidney)
Chemicals/drugs	CHEBI terms for bosentan, sildenafil, tadalafil, iloprost, epoprostenol, treprostinil, macitentan, riociguat
Treatment actions	NCIT:C15986 (Pharmacotherapy), NCIT:C15289 (Organ Transplantation), NCIT:C15329 (Surgical Procedure)
Model organism	NCBITaxon:10090 (mouse)/NCBITaxon:10116 (rat) for aortocaval fistula model; NCBITaxon:9615 (dog) for natural PDA-associated disease

Ask OpenScientist

OpenScientist Report

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Diagnosis

Progression

Prevalence

Clinical Burden

Differential Diagnoses

Related Datasets

Clinical Trials

Source YAML

References & Deep Research

Deep Research

Eisenmenger Syndrome: Comprehensive Research Report

1. Disease Information

2. Etiology

2a. Disease Causal Factors (mechanistic/anatomic)

2b. Risk Factors

2c. Protective Factors

2d. Gene-Environment Interactions

3. Phenotypes

Symptoms / Clinical Signs (HP-mappable)

Onset, Severity, Progression, Frequency

Quality of Life

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream)

Cell types and biological processes involved

Suggested downstream/module conformance

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

Pharmacotherapy (PAH-targeted "disease-targeting therapy," DTT)

Advanced/procedural therapies

Supportive care

Experimental

Suggested NCIT treatment terms

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Summary of Key Ontology Term Suggestions for Curation

Sources